prompt,answer
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 145199.14 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-06-04 to 2023-06-11, AMGN's stock price increased from 214.63 to 215.31. Company news during this period are listed below:

[Headline]: Even Mark Cuban Can’t Fix This Broken Drug System
[Summary]: Coherus BioSciences’ partnership to offer deeply discounted biosimilar Humira can go only so far in reducing overall prices.

[Headline]: Stocks making the biggest moves midday: Palo Alto Networks, 3M, Amedisys, Target and more
[Summary]: These are among the stocks posting the largest moves in midday trading Monday. 

[Headline]: Amgen Inc. stock outperforms competitors on strong trading day
[Summary]: Shares of Amgen Inc. advanced 1.75% to $221.88 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...

[Headline]: Is AbbVie or Amgen the Better Bargain Buy Right Now?
[Summary]: Due to the highly competitive nature of the pharmaceutical industry, it is no easy task to replace the aging stars in a drug portfolio.  Teva Pharmaceutical (NYSE: TEVA) illustrates this point nicely.  In the middle of the last decade, Teva lost exclusivity for its multiple sclerosis medication Copaxone.

[Headline]: Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know
[Summary]: Amgen (AMGN) closed at $218.82 in the latest trading session, marking a -0.88% move from the prior day.

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-06-11, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-06-11 to 2023-06-18) is up by 4-5%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen Inc's stock price outperformed competitors on a challenging trading day, indicating strong investor interest and confidence.
2. Amgen Inc is a key player in the biotechnology industry and continues to drive progress and innovation in the sector.

[Potential Concerns]:
1. The article highlighting the challenges in the pharmaceutical industry and the need to replace aging stars in a drug portfolio may raise concerns about Amgen Inc's ability to maintain its competitive edge.
2. The slight decrease in the stock price at the end of the period may indicate short-term market volatility or investor uncertainty.

[Prediction & Analysis]:
Based on the positive developments and potential concerns, as well as the assumption of a 4-5% increase in stock price for the upcoming week, it is likely that Amgen Inc's stock price will experience moderate growth. The positive performance on a challenging trading day and the company's position as a leading player in the biotechnology industry suggest continued investor interest and confidence. However, the concerns raised in the article regarding the pharmaceutical industry's challenges and the need to replace aging stars may limit potential upside. Overall, the predicted increase in stock price for the upcoming week aligns with the positive developments and reflects a modest expectation for growth."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 145199.14 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-06-04 to 2023-06-11, AMGN's stock price increased from 214.63 to 215.31. Company news during this period are listed below:

[Headline]: Even Mark Cuban Can’t Fix This Broken Drug System
[Summary]: Coherus BioSciences’ partnership to offer deeply discounted biosimilar Humira can go only so far in reducing overall prices.

[Headline]: Amgen Inc. stock outperforms competitors on strong trading day
[Summary]: Shares of Amgen Inc. advanced 1.75% to $221.88 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...

[Headline]: U.S. Wide-Moat Stocks On Sale - The June 2023 Heat Map
[Summary]: Our 3-step process focuses on wide-moat stocks (as per Morningstarâs rating). Click here to see the heat map of the most investable candidates for June 2023.

[Headline]: Amgen Inc. stock underperforms Wednesday when compared to competitors despite daily gains
[Summary]: Shares of Amgen Inc. inched 0.01% higher to $221.25 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...

[Headline]: DJD: Attractive Valuation, Average Quality And Return
[Summary]: DJD holds 27 stocks of the Dow Jones paying a dividend. Valuation and dividend growth look attractive, but quality and historical return are average. Read more here.

From 2023-06-11 to 2023-06-18, AMGN's stock price increased from 215.31 to 226.04. Company news during this period are listed below:

[Headline]: Pharma: M&A strategy gets dose of bitter medicine
[Summary]: Medicines price gouger Martin Shkreli was one of a kind.  Illumina bought cancer test developer Grail for $8bn in 2021, even though US and EU authorities complained the US gene sequencer could deny crucial inputs to Grail’s rivals.  On Monday, its boss Francis deSouza resigned after a proxy fight with activist investor Carl Icahn over Illumina’s decision to proceed.

[Headline]: Microsoft, Amgen share gains lead Dow's nearly 450-point rally
[Summary]: Led by strong returns for shares of Microsoft and Amgen, the Dow Jones Industrial Average is rallying Thursday afternoon. The Dow is trading 445 points...

[Headline]: How Amgen Makes Money
[Summary]: Amgen produces drugs to treat several conditions and markets them worldwide. Learn its revenue-earning structure and how it makes money.

[Headline]: AbbVie's (ABBV) Skyrizi Meets Ulcerative Colitis Study Goals
[Summary]: AbbVie's (ABBV) Skyrizi achieves statistical significance with its primary endpoint of clinical remission in a late-stage study as a maintenance treatment for ulcerative colitis.

[Headline]: Amgen (AMGN) Gains As Market Dips: What You Should Know
[Summary]: In the latest trading session, Amgen (AMGN) closed at $229.66, marking a +0.53% move from the previous day.

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-06-18, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-06-18 to 2023-06-25) is down by 1-2%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen Inc's stock price has shown consistent growth over the past weeks, indicating investor confidence in the company.
2. The company has been outperforming its competitors in the biotechnology sector, suggesting strength in its operations and market positioning.

[Potential Concerns]:
1. The overall market has experienced mixed trading sessions, which could impact Amgen Inc's stock price.
2. The company's financials have not been reported, making it difficult to assess its current financial health.

[Prediction & Analysis]:
Based on the positive developments and potential concerns, as well as the overall market conditions, it is predicted that Amgen Inc's stock price may experience a slight decline of 1-2% in the upcoming week. While the company has shown strength in its stock performance and market positioning, the mixed market conditions and lack of financial information may lead to some profit-taking by investors. Additionally, the absence of basic financials makes it challenging to evaluate the company's current financial health, which could introduce some uncertainty among investors. However, it is important to note that this prediction is based on the available information and market trends, and actual outcomes may vary."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 145199.14 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-06-04 to 2023-06-11, AMGN's stock price increased from 214.63 to 215.31. Company news during this period are listed below:

[Headline]: Analysis-Stelara patent deal puts J&J back on path to $57 billion 2025 revenue forecast
[Summary]: Johnson & Johnson's legal settlement with Amgen Inc to delay a biosimilar version of its blockbuster psoriasis treatment Stelara until January 2025 could make the  drug a larger contributor to J&J’s 2024 and 2025 sales than Wall Street is forecasting.  Stelara, introduced in 2009, has been J&J’s top-selling drug since 2019, with sales reaching $9.7 billion in 2022.  Its patents begin to expire this year, opening the door to a cheaper biosimilar entering the market, and raising expectations that the company would need to lower the $13,000 per month price of Stelara.

[Headline]: Even Mark Cuban Can’t Fix This Broken Drug System
[Summary]: Coherus BioSciences’ partnership to offer deeply discounted biosimilar Humira can go only so far in reducing overall prices.

[Headline]: Amgen Inc. stock underperforms Wednesday when compared to competitors despite daily gains
[Summary]: Shares of Amgen Inc. inched 0.01% higher to $221.25 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...

[Headline]: AMGEN TO PRESENT AT THE GOLDMAN SACHS 44TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
[Summary]: Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 44th Annual Global Healthcare Conference at 2:20 p.m. ET on Wednesday, June 14, 2023. Robert A. Bradway, chairman and chief executive officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors, and the general public.

[Headline]: Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know
[Summary]: Amgen (AMGN) closed at $218.82 in the latest trading session, marking a -0.88% move from the prior day.

From 2023-06-11 to 2023-06-18, AMGN's stock price increased from 215.31 to 226.04. Company news during this period are listed below:

[Headline]: Amgen Inc. stock falls Monday, underperforms market
[Summary]: Shares of Amgen Inc. dropped 0.64% to $217.36 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...

[Headline]: Medifast: A Revamp Is Necessary, An Embrace Of GLP-1s Can Help
[Summary]: Medifast is currently deploying positive cash flow dollars to maintenance of over 8% yielding dividend and to share repurchases. Find out why MED stock is a Strong Buy.

[Headline]: How Amgen Makes Money
[Summary]: Amgen produces drugs to treat several conditions and markets them worldwide. Learn its revenue-earning structure and how it makes money.

[Headline]: A great week that adds to Amgen Inc.'s (NASDAQ:AMGN) one-year returns, institutional investors who own 77% must be happy
[Summary]: Key Insights Institutions' substantial holdings in Amgen implies that they have significant influence over the...

[Headline]: How to Retire Rich: Biotech Stocks Edition
[Summary]: Among the most difficult endeavors when it comes to deciphering the best retirement planning stocks is to identify companies that will remain relevant for years, if not decades to come. While no guarantees exist for anything, those who focus on investing in biotech own a clear advantage. Almost surely, the underlying sector – which falls under the broad healthcare industry – is permanently relevant. Further, I submitted a query on ChatGPT to extract key reasons why biotech stocks for retirement

From 2023-06-18 to 2023-06-25, AMGN's stock price decreased from 226.04 to 223.53. Company news during this period are listed below:

[Headline]: Tracking John Paulson's Paulson & Company Portfolio - Q1 2023 Update
[Summary]: John Paulson's 13F portfolio value increased by around 8% from approximately $1.11B to $1.20B in Q1 2023. Read more on stake increases and decreases here.

[Headline]: Amgen Gets FDA Approval for Blincyto Supplemental Biologics License Application
[Summary]: By Chris Wack Amgen said Wednesday that the U.S. Food and Drug Administration has approved its supplemental biologics license application for Blincyto, a...

[Headline]: FDA GRANTS FULL APPROVAL FOR BLINCYTO® (BLINATUMOMAB) TO TREAT MINIMAL RESIDUAL DISEASE-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
[Summary]: Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BLINCYTO® (blinatumomab) for the treatment of adults and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic leukemia (B-ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%, based on additional data from two Phase 3 studies that were submitted. The approval conver

[Headline]: Amgen Inc. stock outperforms market on strong trading day
[Summary]: Shares of Amgen Inc. rallied 1.15% to $229.66 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...

[Headline]: Amgen Inc. stock underperforms Friday when compared to competitors
[Summary]: Shares of Amgen Inc. slipped 1.11% to $227.11 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...

Some recent basic financials of AMGN, reported at 2023-06-30, are presented below:

[Basic Financials]:

assetTurnoverTTM: 0.3454
bookValue: 6781
cashRatio: 2.0031584488506757
currentRatio: 2.7712
ebitPerShare: 4.9981
eps: 2.568
ev: 146076.7
fcfMargin: 0.5494
fcfPerShareTTM: 18.1028
grossMargin: 0.7405
inventoryTurnoverTTM: 1.4331
longtermDebtTotalAsset: 0.6578
longtermDebtTotalCapital: 0.869
longtermDebtTotalEquity: 8.7564
netDebtToTotalCapital: 0.3995
netDebtToTotalEquity: 4.0254
netMargin: 0.1974
operatingMargin: 0.3842
payoutRatioTTM: 0.5457
pb: 17.5167
peTTM: 14.8867
pfcfTTM: 12.2644
pretaxMargin: 0.231
psTTM: 4.4685
quickRatio: 2.4801
receivablesTurnoverTTM: 4.7651
roaTTM: 0.1037
roeTTM: 1.6415
roicTTM: 0.1449
rotcTTM: 0.1759
salesPerShare: 13.0093
sgaToSale: 0.2595
totalDebtToEquity: 9.0759
totalDebtToTotalAsset: 0.6818
totalDebtToTotalCapital: 0.9008
totalRatio: 1.0812

Based on all the information before 2023-06-25, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-06-25 to 2023-07-02) is down by 2-3%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen's Stelara patent deal with Johnson & Johnson could protect its market share and revenue by delaying the entry of a cheaper biosimilar version of the drug until 2025.
2. Amgen received FDA approval for its supplemental biologics license application for Blincyto, a drug used in the treatment of B-cell precursor acute lymphoblastic leukemia.

[Potential Concerns]:
1. Despite some positive news, Amgen's stock underperformed its competitors on certain trading sessions.
2. Coherus BioSciences' partnership to offer deeply discounted biosimilar Humira could pose a challenge in terms of price competition in the biotech space.

[Prediction & Analysis]:
Based on the positive developments and potential concerns, as well as the recent stock price movement, it is predicted that Amgen's stock price could decrease by 2-3% in the upcoming week (2023-06-25 to 2023-07-02). While Amgen has secured a patent deal and received FDA approval for one of its drugs, the underperformance of the stock compared to competitors and potential price competition in the market may contribute to a slight decline in the stock price. Additionally, the overall mixed trading sessions in the stock market can add uncertainty and potentially impact the stock price negatively."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 145199.14 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-06-25 to 2023-07-02, AMGN's stock price decreased from 223.53 to 218.52. Company news during this period are listed below:

[Headline]: Why Amgen Stock Slumped on Monday
[Summary]: Amgen (NASDAQ: AMGN) stock came under renewed pressure on Monday, several days after more regulators piled on to block a major acquisition announced by the company.  As a result, Amgen's share price sank by slightly over 1%, which was more than double the percentage-rate decline of the S&P 500 index on the day.  The person taking the scissors to his Amgen price target was Argus Research's David Toung.

[Headline]: Argus Research Maintains AMGEN (AMGN) Buy Recommendation
[Summary]: 

[Headline]: Dow Jones Today: Index Ends 6-Day Losing Streak
[Summary]: Tech and retail stocks helped lift the Dow Jones, while Walgreens plummeted after lowering its earnings outlook

[Headline]: 5 High-Yielding Dividend Stocks That Are Bargain Buys
[Summary]: If you're in search of bargain stocks to buy, the healthcare industry is a great place to start looking.  Among them are Johnson & Johnson (NYSE: JNJ), AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), Amgen (NASDAQ: AMGN), and Pfizer (NYSE: PFE) -- all of which pay dividends and offer great value.

[Headline]: Moody's: Pharma outlook stable for next 12-18 months, but with caveats
[Summary]: Moody's, in a note, sees a stable outlook for the drug industry. But there are a few headwinds that might mess up the semi-optimistic picture.

Some recent basic financials of AMGN, reported at 2023-06-30, are presented below:

[Basic Financials]:

assetTurnoverTTM: 0.3454
bookValue: 6781
cashRatio: 2.0031584488506757
currentRatio: 2.7712
ebitPerShare: 4.9981
eps: 2.568
ev: 146076.7
fcfMargin: 0.5494
fcfPerShareTTM: 18.1028
grossMargin: 0.7405
inventoryTurnoverTTM: 1.4331
longtermDebtTotalAsset: 0.6578
longtermDebtTotalCapital: 0.869
longtermDebtTotalEquity: 8.7564
netDebtToTotalCapital: 0.3995
netDebtToTotalEquity: 4.0254
netMargin: 0.1974
operatingMargin: 0.3842
payoutRatioTTM: 0.5457
pb: 17.5167
peTTM: 14.8867
pfcfTTM: 12.2644
pretaxMargin: 0.231
psTTM: 4.4685
quickRatio: 2.4801
receivablesTurnoverTTM: 4.7651
roaTTM: 0.1037
roeTTM: 1.6415
roicTTM: 0.1449
rotcTTM: 0.1759
salesPerShare: 13.0093
sgaToSale: 0.2595
totalDebtToEquity: 9.0759
totalDebtToTotalAsset: 0.6818
totalDebtToTotalCapital: 0.9008
totalRatio: 1.0812

Based on all the information before 2023-07-02, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-07-02 to 2023-07-09) is down by 1-2%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Argus Research maintained a buy recommendation for AMGN, indicating confidence in the company's future prospects.
2. Amgen was included in a list of high-yielding dividend stocks that are considered bargain buys, highlighting its potential value and income generation for investors.

[Potential Concerns]:
1. Amgen's stock price slumped after additional regulators blocked a major acquisition announced by the company, creating uncertainty about future growth opportunities.
2. Moody's noted some headwinds that could impact the drug industry, which could potentially affect Amgen's operations and financial performance.

[Prediction & Analysis]:
Based on the positive developments and potential concerns, as well as the recent decline in Amgen's stock price, it is likely that the stock will continue its downward trend in the upcoming week. The negative impact of the blocked acquisition, coupled with the overall uncertainty in the drug industry, could weigh on investor sentiment and result in a decrease in Amgen's stock price. Additionally, a decline of 1-2% seems plausible considering the recent market conditions and the specific concerns surrounding the company."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 145199.14 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-07-02 to 2023-07-09, AMGN's stock price decreased from 218.52 to 215.20. Company news during this period are listed below:

[Headline]: Not A Market For The Dogs Of The Dow
[Summary]: With the first half of 2023 coming to a close this past Friday, the equity markets rewarded investors with strong performance.

[Headline]: 5 Top Dividend Stocks For July 2023
[Summary]: The S&P 500 gained 16% through the first half of 2023. Click here to read more about the five dividend stocks to consider buying in July 2023.

[Headline]: Amgen Inc. stock rises Wednesday, outperforms market
[Summary]: Shares of Amgen Inc. inched 0.39% higher to $225.88 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...

[Headline]: U.S. Wide-Moat Stocks On Sale - The July 2023 Heat Map
[Summary]: Our 3-step process focuses on wide-moat stocks. We're only interested in targets attractively valued in historical comparison. Read what investors need to know.

[Headline]: 2 Struggling Dividend Growth Stocks That Could Make You Richer
[Summary]: Despite lingering economic issues, the broader stock market has recovered this year.  Take AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN), two drugmakers that have significantly underperformed the stock market this year.  AbbVie started the year with a lot to prove.

Some recent basic financials of AMGN, reported at 2023-06-30, are presented below:

[Basic Financials]:

assetTurnoverTTM: 0.3454
bookValue: 6781
cashRatio: 2.0031584488506757
currentRatio: 2.7712
ebitPerShare: 4.9981
eps: 2.568
ev: 146076.7
fcfMargin: 0.5494
fcfPerShareTTM: 18.1028
grossMargin: 0.7405
inventoryTurnoverTTM: 1.4331
longtermDebtTotalAsset: 0.6578
longtermDebtTotalCapital: 0.869
longtermDebtTotalEquity: 8.7564
netDebtToTotalCapital: 0.3995
netDebtToTotalEquity: 4.0254
netMargin: 0.1974
operatingMargin: 0.3842
payoutRatioTTM: 0.5457
pb: 17.5167
peTTM: 14.8867
pfcfTTM: 12.2644
pretaxMargin: 0.231
psTTM: 4.4685
quickRatio: 2.4801
receivablesTurnoverTTM: 4.7651
roaTTM: 0.1037
roeTTM: 1.6415
roicTTM: 0.1449
rotcTTM: 0.1759
salesPerShare: 13.0093
sgaToSale: 0.2595
totalDebtToEquity: 9.0759
totalDebtToTotalAsset: 0.6818
totalDebtToTotalCapital: 0.9008
totalRatio: 1.0812

Based on all the information before 2023-07-09, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-07-09 to 2023-07-16) is up by 4-5%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen Inc's stock price rose during a dismal trading session, showing resilience and outperforming the broader market.
2. The company is recognized as one of the top dividend stocks to consider buying in July 2023, which indicates investor interest and potential for stable returns.

[Potential Concerns]:
1. Amgen Inc, along with Abbott Laboratories, is mentioned as a struggling dividend growth stock. This suggests that there may be challenges or underperformance affecting the stock.
2. The stock price decreased slightly from the previous week, indicating some volatility in the market and potential negative sentiment.

[Prediction & Analysis]:
Despite the slight decrease in the stock price over the analyzed period, Amgen Inc has shown positive developments such as outperforming the market during a tough trading session and being recognized as a top dividend stock. These factors indicate that the company has the potential to rebound in the upcoming week.

Assuming a 4-5% increase in the stock price for the next week, this prediction is based on the resilience and outperformance exhibited by Amgen Inc amid market volatility, as well as the potential for stable returns from being considered a top dividend stock. Additionally, the positive developments outweigh the potential concerns mentioned, further supporting the prediction of a positive stock price movement.

However, it is important to note that stock market predictions are subject to various external factors and uncertainties, and investors should conduct thorough research and analysis before making any investment decisions."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 145199.14 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-06-18 to 2023-06-25, AMGN's stock price decreased from 226.04 to 223.53. Company news during this period are listed below:

[Headline]: Drugmakers aim to strike down Medicare drug-price negotiations at Supreme Court 
[Summary]: The lawsuits are the opening salvo in a historic and potentially decisive battle over Medicare's efforts to bring rising drug prices under control. 

[Headline]: Tracking John Paulson's Paulson & Company Portfolio - Q1 2023 Update
[Summary]: John Paulson's 13F portfolio value increased by around 8% from approximately $1.11B to $1.20B in Q1 2023. Read more on stake increases and decreases here.

[Headline]: Leveraging AI in Drug Discovery: Elizabeth Schwarzbach of BigHat Biosciences, Live from NYSE
[Summary]: IPO Edge hosted a fireside chat from the floor of the New York Stock Exchange with Elizabeth Schwarzbach, Chief Business Officer of BigHat Biosciences. She spoke to IPO Edge Editor-in-Chief […]

[Headline]: California, other states join FTC bid to block Amgen deal
[Summary]: The states of California, New York, Illinois, Minnesota,  Washington and Wisconsin have joined a Federal Trade Commission (FTC) lawsuit to stop Amgen's $27.8 billion deal to buy Horizon Therapeutics, according to a court filing on Thursday.  Washington Attorney General Bob Ferguson said his state had joined the lawsuit because ""monopolies harm consumers"" and the merger could allow Amgen to ""dominate"" prescription drug markets.  The group of six states filed an amended complaint Thursday, joining the FTC which last month filed suit opposing the deal because it would give Amgen ""monopoly positions"" for medicines used to treat thyroid eye disease and chronic refractory gout.

[Headline]: UPDATE 1-California, other states join FTC bid to block Amgen deal
[Summary]: The states of California, New York, Illinois, Minnesota,  Washington and Wisconsin have joined a Federal Trade Commission (FTC) lawsuit to stop Amgen's $27.8 billion deal to buy Horizon Therapeutics, according to a court filing on Thursday.  Washington Attorney General Bob Ferguson said his state had joined the lawsuit because ""monopolies harm consumers"" and the merger could allow Amgen to ""dominate"" prescription drug markets.  The group of six states filed an amended complaint Thursday, joining the FTC which last month filed suit opposing the deal because it would give Amgen ""monopoly positions"" for medicines used to treat thyroid eye disease and chronic refractory gout.

From 2023-06-25 to 2023-07-02, AMGN's stock price decreased from 223.53 to 218.52. Company news during this period are listed below:

[Headline]: Dow falls 109 points on losses for Amgen, Johnson & Johnson shares
[Summary]: Behind losses for shares of Amgen and Johnson & Johnson, the Dow Jones Industrial Average is down Monday morning. The Dow was most recently trading 109...

[Headline]: Amgen Inc. stock falls Wednesday, underperforms market
[Summary]: Shares of Amgen Inc. slid 0.58% to $221.31 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...

[Headline]: The New M&A Rules That Would Delay Million-Dollar Deals
[Summary]: (Bloomberg) -- The US antitrust agencies are requiring firms to turn over much more information about their transactions than before in an overhaul to merger rules that could delay deals by months. Most Read from BloombergPutin Claims He’s Back in Control. Russia’s Elite Isn’t SureSwitzerland Blocks Sale of Leopard 1 Tanks Bound for UkraineQatar Group Now Confident of Winning Manchester United RaceSweden Police Give Permit to Koran Burning Near Stockholm MosqueUBS Preparing to Cut Over Half of C

[Headline]: What Will Amgen Buy Next?
[Summary]: Biotech heavyweight Amgen (NASDAQ: AMGN) will probably continue to be an active player in the merger and acquisition (M&A) scene, regardless of what happens with its proposed $28 billion buyout of Horizon Therapeutics (NASDAQ: HZNP).  If this acquisition goes through, for instance, Amgen will probably be limited to smaller deals under $10 billion.

[Headline]: Amgen Inc. stock rises Friday, still underperforms market
[Summary]: Shares of Amgen Inc. inched 0.39% higher to $222.02 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...

From 2023-07-02 to 2023-07-09, AMGN's stock price decreased from 218.52 to 215.20. Company news during this period are listed below:

[Headline]: 3 Biotech Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2025
[Summary]: Investing in the biotech sector is mostly about risk and reward. When a company achieves FDA approval on a drug or therapeutic, it frequently has a source of revenue and profit that can last for years. And investors who buy and hold these stocks are typically rewarded with handsome total returns. Even penny stocks can become triple-digit return biotech stocks. However, that payoff can take a long time. Just getting a drug through the clinical trial stage can take several years. And some candidat

[Headline]: Rose's Income Garden 80 Stock Portfolio: Update H1 2023 Green With 7 June Raises
[Summary]: Rose's Income Garden portfolio saw 39 companies pay dividends in June, with seven raises and one cut. Click here for a detailed analysis.

[Headline]: Amgen (NASDAQ:AMGN) shareholders have earned a 5.8% CAGR over the last five years
[Summary]: Amgen Inc. ( NASDAQ:AMGN ) shareholders might be concerned after seeing the share price drop 12% in the last quarter...

[Headline]: 2 Struggling Dividend Growth Stocks That Could Make You Richer
[Summary]: Despite lingering economic issues, the broader stock market has recovered this year.  Take AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN), two drugmakers that have significantly underperformed the stock market this year.  AbbVie started the year with a lot to prove.

[Headline]: Amgen (AMGN) Dips More Than Broader Markets: What You Should Know
[Summary]: In the latest trading session, Amgen (AMGN) closed at $218.65, marking a -1.94% move from the previous day.

From 2023-07-09 to 2023-07-16, AMGN's stock price increased from 215.20 to 223.84. Company news during this period are listed below:

[Headline]: EU expands Wegovy, Ozempic probe over suicide risks to include other weight loss, diabetes drugs
[Summary]: The European Medicines Agency didn't specify which additional GLP-1 drugs are now being investigated, but it could potentially include Eli Lilly's Mounjaro. 

[Headline]: ClearBridge Small Cap Growth Strategy Q2 2023 Portfolio Manager Commentary
[Summary]: The growth rally expanded to smaller stocks in the second quarter. Click here to read the full fund letter.

[Headline]: The Blazing Weight-Loss Drug Battle: Can Anyone Unseat Undisputed Leaders Novo Nordisk And Lilly?
[Summary]: An overweight world is hungry for obesity treatments, driving big forecasts for weight loss drugs. For now, two pharmaceutical stocks own the market.

[Headline]: MOORE KUEHN ENCOURAGES AMGEN INC. INVESTORS TO CONTACT LAW FIRM
[Summary]: NEW YORK, July 14, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a securities and shareholder law firm located on Wall Street, is investigating potential claims against:

    
                
           ...

[Headline]: Amgen Inc. stock outperforms market despite losses on the day
[Summary]: Shares of Amgen Inc. slumped 0.10% to $227.43 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-07-16, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-07-16 to 2023-07-23) is up by 3-4%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. The stock price of AMGN increased from 215.20 to 223.84 during the past week, indicating positive momentum.
2. EU expanding probe to include other weight loss and diabetes drugs, which could potentially benefit AMGN if its drugs are found to be safe and effective.

[Potential Concerns]:
1. Lawsuits and opposition from states regarding the merger with Horizon Therapeutics could impact AMGN's growth prospects and create uncertainty.
2. Shareholders earned a 5.8% CAGR over the last five years, which is lower compared to the broader stock market performance.

[Prediction & Analysis]:
Based on the recent positive momentum in AMGN's stock price, as well as the potential benefits from the expanded EU probe on weight loss and diabetes drugs, it is likely that the stock will continue to perform positively in the upcoming week. Additionally, the concerns regarding the merger and the lower CAGR for shareholders can be mitigated by the positive developments. Therefore, I predict that AMGN's stock price will increase by 3-4% in the next week."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 145199.14 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-07-16 to 2023-07-23, AMGN's stock price increased from 223.84 to 231.12. Company news during this period are listed below:

[Headline]: 3 Biotech Stocks for Getting Rich in 2023
[Summary]: The biotech industry is constantly evolving due to being on the cutting edge of the healthcare industry’s research and development. Large biotech companies such as Johnson and Johnson (NYSE:JNJ), Merck (NYSE:MRK), and AbbVie (NYSE:ABBV) offer investors steady and continual growth as well as decent dividends. But, a large portion of the industry involves much more volatile stocks. Many companies’ significant volatility in the biotech market attracts investors looking for a stock that will experie

[Headline]: Prediction: This Beaten-Down Stock Will Be a Biotech Giant by 2030
[Summary]: When you think of biotech giants, you may think of Amgen or Biogen. These companies have brought significant treatments to market over time -- and have generated billions of dollars in earnings, too. Most investors would be happy to find the next company set to follow in their footsteps.

[Headline]: Amgen Inc. stock falls Wednesday, underperforms market
[Summary]: Shares of Amgen Inc. dropped 0.22% to $232.05 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...

[Headline]: M&A Scrutiny May Constrain Large Companies
[Summary]: The FTCâs recent push against some large M&A deals may ultimately limit the ability of major companies to take advantage of business development opportunities.

[Headline]: Amgen Inc. stock underperforms Friday when compared to competitors despite daily gains
[Summary]: Shares of Amgen Inc. inched 0.68% higher to $234.82 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-07-23, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-07-23 to 2023-07-30) is up by 0-1%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen Inc. is recognized as a leading entity in the Biotechnology sector, known for its innovative and progressive initiatives within the industry.
2. The biotech industry as a whole is experiencing growth and attracting investors looking for potential high returns.
3. Amgen has a track record of bringing significant treatments to the market and generating substantial earnings.

[Potential Concerns]:
1. Amgen Inc.'s stock price experienced a slight drop during the analyzed period, underperforming compared to competitors, despite overall gains in the stock market. This might indicate potential weakness or lack of confidence in the company.
2. The recent scrutiny and potential limitations on large M&A deals by regulatory agencies, such as the FTC, could impact Amgen's ability to pursue business development opportunities, hampering potential growth prospects.

[Prediction & Analysis]:
Considering the positive developments, Amgen's strong market position and past success in bringing treatments to market are encouraging factors. However, the recent underperformance of the stock and the potential constraints on business development due to regulatory scrutiny raise concerns. 

Based on these factors, it is predicted that Amgen Inc's stock price will experience a modest increase of around 0-1% in the upcoming week. This prediction takes into account the overall positive sentiment towards the biotech industry, but also acknowledges the potential challenges and uncertainties associated with the company's performance and regulatory environment."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 145199.14 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-07-16 to 2023-07-23, AMGN's stock price increased from 223.84 to 231.12. Company news during this period are listed below:

[Headline]: 3 Biotech Stocks for Getting Rich in 2023
[Summary]: The biotech industry is constantly evolving due to being on the cutting edge of the healthcare industry’s research and development. Large biotech companies such as Johnson and Johnson (NYSE:JNJ), Merck (NYSE:MRK), and AbbVie (NYSE:ABBV) offer investors steady and continual growth as well as decent dividends. But, a large portion of the industry involves much more volatile stocks. Many companies’ significant volatility in the biotech market attracts investors looking for a stock that will experie

[Headline]: 12 Highest Yielding Dow Jones Dividend Stocks
[Summary]: In this article, we discuss 12 highest yielding Dow Jones dividend stocks. You can skip our detailed analysis of dividend stocks and their performance in the past, and go directly to read 5 Highest Yielding Dow Jones Dividend Stocks. The Dow Jones Industrial Average, commonly referred to as the Dow, is one of the most […]

[Headline]: Amgen Inc. stock outperforms market on strong trading day
[Summary]: Shares of Amgen Inc. inched 0.51% higher to $233.23 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...

[Headline]: M&A Scrutiny May Constrain Large Companies
[Summary]: The FTCâs recent push against some large M&A deals may ultimately limit the ability of major companies to take advantage of business development opportunities.

[Headline]: The 3 Most Undervalued Pharma Stocks to Buy Now: July 2023
[Summary]: Pharma stocks experienced an abysmal first half due to various factors. Rotation from defensive to cyclical sectors, drug price negotiations and upcoming patent cliffs have muddied the outlook. As a result, they have underperformed, creating undervalued pharma stocks to buy. Overall, the VanEck Pharmaceutical ETF (NASDAQ:PPH) is flat for the year. Only a few stocks have performed well. For instance, as of this writing, Eli Lilly (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) are up 23% and 16.67%, r

From 2023-07-23 to 2023-07-30, AMGN's stock price increased from 231.12 to 232.64. Company news during this period are listed below:

[Headline]: Bicara Therapeutics Expands Management Team with the Appointment of David Raben, M.D., as Chief Medical Officer
[Summary]: CAMBRIDGE - Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced the appointment of David...

[Headline]: Amgen Inc. stock underperforms Wednesday when compared to competitors
[Summary]: Shares of Amgen Inc. dropped 0.04% to $235.21 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...

[Headline]: Amgen Inc. stock underperforms Thursday when compared to competitors despite daily gains
[Summary]: Shares of Amgen Inc. inched 0.36% higher to $236.05 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...

[Headline]: AbbVie (ABBV) Beats on Q2 Earnings & Sales, Raises '23 View
[Summary]: AbbVie's (ABBV) second-quarter 2023 earnings and sales beat estimates. The company raises its EPS guidance. Stock rises post the announcement.

[Headline]: With Hurricane Season Looming, Florida Faces an Insurance Meltdown 
[Summary]: Florida has long had hurricanes. But climate change is kicking in, the population of the state is growing, and private insurers are leaving the state. The...

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-07-30, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-07-30 to 2023-08-06) is up by 2-3%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen Inc outperformed the market on a strong trading day, indicating investor confidence.
2. The appointment of David Raben as Chief Medical Officer at Bicara Therapeutics, a clinical-stage biotechnology company, showcases potential collaborations and advancements in the sector.

[Potential Concerns]:
1. Amgen's stock underperformed compared to competitors on certain trading days, suggesting possible challenges in maintaining a competitive edge.
2. Scrutiny on M&A deals by the FTC may limit business development opportunities for major companies like Amgen.

[Prediction & Analysis]:
Based on the positive developments, such as outperforming the market on a strong trading day and the appointment of a chief medical officer at Bicara Therapeutics, Amgen Inc could continue to see positive momentum in the upcoming week. Additionally, the overall growth in the biotech industry and the potential for collaborations could further support Amgen's stock price. However, the underperformance compared to competitors and the potential constraints on M&A deals may pose challenges. Considering these factors, it is predicted that Amgen's stock price could increase by 2-3% in the next week."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 145199.14 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-07-09 to 2023-07-16, AMGN's stock price increased from 215.20 to 223.84. Company news during this period are listed below:

[Headline]: Dow up 182 points on gains for Amgen, Walgreens Boots stocks
[Summary]: The Dow Jones Industrial Average is climbing Monday morning with shares of Amgen and Walgreens Boots leading the way for the index. The Dow is trading 182...

[Headline]: ClearBridge Small Cap Growth Strategy Q2 2023 Portfolio Manager Commentary
[Summary]: The growth rally expanded to smaller stocks in the second quarter. Click here to read the full fund letter.

[Headline]: Let's Check the Safety and Efficacy of Amgen's Charts Ahead of Earnings
[Summary]: AMGN's quarterly report is due in early August, so will buying the stock now pose any side effects?

[Headline]: Lucy Scientific Scores Richard Nanula as CEO After Senior Roles at Disney, Amgen, Starwood
[Summary]: By Daniella Parra Psychotropic industry innovator Lucy Scientific Discovery Inc. (Nasdaq: LSDI), has appointed Richard Nanula, former CFO at Amgen Inc. (Nasdaq: AMGN) and The Walt Disney Co. (NYSE: DIS), as its new CEO. With a career spanning senior executive positions at global giants like Starwood Hotels and Resorts, now part of Marriott International, Inc. […]

[Headline]: Amgen Inc. stock outperforms market on strong trading day
[Summary]: Shares of Amgen Inc. inched 0.88% higher to $227.66 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...

From 2023-07-16 to 2023-07-23, AMGN's stock price increased from 223.84 to 231.12. Company news during this period are listed below:

[Headline]: Regional banks, Dow Theory: Key technical levels to watch
[Summary]: PNC Financial kicked off regional bank earnings with a mixed report. Freedom Capital Markets Chief Global Strategist Jay Woods breaks down what price levels he is watching for the regional banks. For the broader market, with the Dow Jones Industrials Average and the Dow Transports making new 52-week highs, Woods says ""that's as bullish as you can get"" for stocks.

[Headline]: Softbank, Amgen-Backed Neumora Therapeutics Unveils Plans For Three Phase 3 Studies For Major Depressive Disorder
[Summary]: Neumora Therapeutics unveiled plans for three late-stage studies for its major depressive disorder (MDD) candidate Navacaprant. The U.S.-based clinical-stage biopharmaceutical is backed by Softbank Group Corp (OTC: SFTBY) (OTC: SFTBF) and Amgen Inc (NASDAQ: AMGN) via a $100 million equity investment. Neumora's KOASTAL Phase 3 program, comprising three Phase 3 studies, is designed to evaluate 80 mg of the once-daily navacaprant (NMRA-140) oral monotherapy for MDD. The U.S. trial, the KOASTAL-1 st

[Headline]: ClearBridge Large Cap Value ESG Strategy Q3 2023 Portfolio Manager Commentary
[Summary]: ClearBridge takes a fundamental-driven approach to proxies. Click here to read the full fund letter.

[Headline]: 12 Highest Yielding Dow Jones Dividend Stocks
[Summary]: In this article, we discuss 12 highest yielding Dow Jones dividend stocks. You can skip our detailed analysis of dividend stocks and their performance in the past, and go directly to read 5 Highest Yielding Dow Jones Dividend Stocks. The Dow Jones Industrial Average, commonly referred to as the Dow, is one of the most […]

[Headline]: The 3 Most Undervalued Pharma Stocks to Buy Now: July 2023
[Summary]: Pharma stocks experienced an abysmal first half due to various factors. Rotation from defensive to cyclical sectors, drug price negotiations and upcoming patent cliffs have muddied the outlook. As a result, they have underperformed, creating undervalued pharma stocks to buy. Overall, the VanEck Pharmaceutical ETF (NASDAQ:PPH) is flat for the year. Only a few stocks have performed well. For instance, as of this writing, Eli Lilly (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) are up 23% and 16.67%, r

From 2023-07-23 to 2023-07-30, AMGN's stock price increased from 231.12 to 232.64. Company news during this period are listed below:

[Headline]: Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
[Summary]: Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

[Headline]: Mirati (MRTX) Down 7% on CHMP's Opinion on Krazati Filing
[Summary]: Per the CHMP, Mirati's (MRTX) regulatory filing for Krazati in KRASG12C mutated NSCLC does not fulfill certain requirements to support a conditional marketing authorization.

[Headline]: Amgen Inc. stock rises Monday, still underperforms market
[Summary]: Shares of Amgen Inc. inched 0.26% higher to $235.42 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...

[Headline]: Janux: Merck Deal, Loads Of Cash, Solid Early Data
[Summary]: Janux Therapeutics is a small company with a deal from Merck & Co. and some solid early data. Click here for my look at JANX stock prospects.

[Headline]: INVESTIGATION ALERT : Scott+Scott Attorneys at Law LLP Investigates Amgen Inc's Directors and Officers for Breach of Fiduciary Duties – AMGN
[Summary]: Scott+Scott Attorneys at Law LLP , an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of Amgen Inc.   breached their fiduciary...

From 2023-07-30 to 2023-08-06, AMGN's stock price increased from 232.64 to 239.44. Company news during this period are listed below:

[Headline]: Amgen Inc. stock falls Monday, underperforms market
[Summary]: Shares of Amgen Inc. dropped 0.94% to $234.15 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...

[Headline]: AMGEN ANNOUNCES WEBCAST OF 2023 SECOND QUARTER FINANCIAL RESULTS
[Summary]: Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Thursday, August 3, 2023, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 1:30 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.

[Headline]: Amgen Inc. (AMGN) Q2 2023 Earnings Call Transcript
[Summary]: Amgen Inc. (NASDAQ:NASDAQ:AMGN) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ETCompany ParticipantsArvind Sood â Vice President of Investor RelationsBob Bradway â Chairman and...

[Headline]: Amgen (AMGN) Reports Q2 Earnings: What Key Metrics Have to Say
[Summary]: While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

[Headline]: Amgen Is 'Confident' It Can Wrap The Horizon Takeover By December
[Summary]: Amgen stock jumped Friday after topping Wall Street's second-quarter views, but investors remain zeroed in on the takeover of Horizon.

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-08-06, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-08-06 to 2023-08-13) is up by more than 5%+. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen's stock price has been steadily increasing over the past weeks, reaching new highs.
2. Amgen announced the appointment of Richard Nanula, a former CFO at Amgen Inc., as the new CEO of Lucy Scientific Discovery Inc., which highlights the company's ability to attract top industry talent and potentially drive future innovation.
3. Amgen's collaboration with Neumora Therapeutics for the development of a major depressive disorder candidate indicates the company's efforts to expand its product portfolio and enter new therapeutic areas.

[Potential Concerns]:
1. A law firm has launched an investigation into Amgen Inc.'s directors and officers for potential breach of fiduciary duties, which could lead to legal and reputational challenges for the company.
2. The recent drop in Amgen's stock price suggests that the market may have concerns or uncertainties regarding the company's performance and outlook.

[Prediction & Analysis]:
Based on the positive developments and potential concerns, as well as the overall trend of Amgen's stock price, it is likely that the stock will continue to increase in the upcoming week. The positive news surrounding the company, such as the appointment of a new CEO, collaborations in new therapeutic areas, and the overall upward trend in stock price, indicate that investors have a positive view of Amgen's prospects. However, the potential concerns, including the ongoing investigation into the company's directors and officers and the recent drop in stock price, cannot be ignored. These factors may introduce a certain level of volatility and uncertainty to the stock movement. Considering all of these factors, the prediction for the upcoming week is for Amgen's stock price to increase by more than 5%."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 145199.14 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-08-06 to 2023-08-13, AMGN's stock price increased from 239.44 to 258.37. Company news during this period are listed below:

[Headline]: Stock futures rise as Wall Street comes off a losing week: Live updates
[Summary]: Last week was the worst for the S&P 500 and Nasdaq Composite since March.

[Headline]: The 3 Best Biotech Stocks to Buy in August
[Summary]: Many healthcare stocks suffer from COVID fatigue as profits fall amid a global decline in the virus’ spread. But medical innovations and technological breakthroughs are rapidly transforming the healthcare landscape, and biotech stocks are garnering unprecedented attention in the investment community. These companies, operating at the intersection of biology and technology, promise groundbreaking treatments, therapies and solutions to some of the world’s most persistent medical challenges. As the

[Headline]: Want Rising Dividend Income? Buy Amgen Stock
[Summary]: Pharmaceutical company Amgen (NASDAQ: AMGN) is a favorite among income investors.  Here are four reasons that the stock could have a special place in a portfolio centered around dividend growth.  In the second quarter ended June 30, Amgen's total revenue increased by 5.9% year over year to $7 billion.

[Headline]: Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
[Summary]: Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

[Headline]: 3 Dow Jones Stocks To Watch In August 2023
[Summary]: Dow Jones Industrial Average stocks to check out in the stock market today.

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-08-13, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-08-13 to 2023-08-20) is up by 0-1%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. The stock price of AMGN has been on an upward trend, increasing from 239.44 to 258.37 during the past week.
2. Amgen's total revenue for the second quarter showed a significant year-over-year increase of 5.9%, reaching $7 billion.

[Potential Concerns]:
1. The overall market sentiment, as indicated by the worst week for the S&P 500 and Nasdaq Composite since March, may negatively impact AMGN's stock price.
2. The COVID fatigue affecting healthcare stocks could potentially dampen investor enthusiasm for Amgen despite its innovative treatments and therapies.

[Prediction & Analysis]:
Based on the positive developments mentioned above, including the upward trend in the stock price and the strong second-quarter revenue growth, there is a positive sentiment surrounding AMGN. It is also encouraging to see Amgen gaining attention from investors and being mentioned as one of the top biotech stocks to buy.

However, the potential concerns related to market sentiment and the impact of COVID fatigue cannot be ignored. These factors may inject some volatility into AMGN's stock price.

Considering these factors, it is reasonable to predict that AMGN's stock price will continue to show some upward momentum in the upcoming week. However, due to the mentioned concerns, it is unlikely to see a significant increase. Therefore, a prediction of up by 0-1% for AMGN's stock price during the next week seems reasonable."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 145199.14 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-08-13 to 2023-08-20, AMGN's stock price increased from 258.37 to 259.78. Company news during this period are listed below:

[Headline]: August MDA Breakout Stocks Week 33 - 2023: Facing The Largest Negative Signal Since February
[Summary]: The Momentum Gauges and S&P 500 Gauges have turned negative. Read why this indicates a shift in market momentum and the need for caution in stock selection.

[Headline]: Improved Outlook For Horizon Therapeutics And Amgen
[Summary]: Horizon Therapeutics' better-than-expected Q2 eases concerns about Amgen acquisition failing to close due to Horizon's business underperformance. Read more here.

[Headline]: Amgen Stock Scores Relative Strength Rating Upgrade; Hits Key Benchmark
[Summary]: Amgen shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 68 to 80.

[Headline]: Unusual Call Option Trade in AMGEN (AMGN)  Worth $4,395.60K
[Summary]: 

[Headline]: With 78% ownership of the shares, Amgen Inc. (NASDAQ:AMGN) is heavily dominated by institutional owners
[Summary]: Key Insights Given the large stake in the stock by institutions, Amgen's stock price might be vulnerable to their...

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-08-20, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-08-20 to 2023-08-27) is down by 2-3%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Improved Outlook for Horizon Therapeutics and Amgen: The better-than-expected Q2 performance of Horizon Therapeutics has eased concerns about the acquisition of Amgen falling through. This indicates potential positive synergies and growth prospects for Amgen.
2. Amgen Stock Scores Relative Strength Rating Upgrade: The upgrade of Amgen's IBD Relative Strength Rating from 68 to 80 indicates a rising price performance and suggests positive momentum in the stock.

[Potential Concerns]:
1. Negative Signal in Market Momentum: The negative signal in the Momentum Gauges and S&P 500 Gauges raises caution in stock selection. This may impact the overall market sentiment, including towards Amgen.
2. Institutional Ownership: With 78% ownership of the shares by institutional owners, Amgen's stock price might be vulnerable to their actions and decisions, which could introduce potential volatility.

[Prediction & Analysis]:
Based on the provided information, it is expected that the stock price of Amgen (AMGN) may decline by 2-3% in the upcoming week (2023-08-20 to 2023-08-27). The positive developments, such as the improved outlook for the Horizon Therapeutics acquisition and the relative strength rating upgrade, could provide some support for the stock. However, the negative signal in market momentum and the influence of institutional ownership may generate concerns and potentially impact the stock price negatively.

Considering the cautious market sentiment indicated by the negative momentum signal and the vulnerability to institutional actions, investors might choose to take profits or adopt a wait-and-see approach. Consequently, the downward pressure on the stock price is expected to outweigh the positive factors, leading to a decline of 2-3% in the upcoming week."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 145199.14 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-08-06 to 2023-08-13, AMGN's stock price increased from 239.44 to 258.37. Company news during this period are listed below:

[Headline]: Amgen Gives You Growth, Dividend Growth, And Value
[Summary]: Amgen appears to remain undervalued for value and income investors. Read more to see a detailed analysis of AMGN stock.

[Headline]: August MDA Breakout Stocks Week 32 - 2023: High-Frequency Gainers To Give You An Edge
[Summary]: Two new Breakout Stocks for Week 32 curated by the MDA model for 10% short-term upside and additional model selections. Click here to read more.

[Headline]: 3 Biotech Stocks You’ll Regret Not Buying Soon
[Summary]: The biotech industry proved itself resilient in the face of the COVID-19 pandemic. With research from Mckinsey, venture capitalist (VC) companies increased investments from 2,200 in 2016 to 3,100 in 2021 in biotechnology (biotech) startups. These startups have advanced medicine overall, improving cell therapy, tissue regeneration, genetic medicine, and more. With increasing innovation, we see an ongoing cycle. VC companies will continue to invest by providing resources and funding for these comp

[Headline]: Amgen (NASDAQ:AMGN) jumps 13% this week, though earnings growth is still tracking behind five-year shareholder returns
[Summary]: When you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than...

[Headline]: Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
[Summary]: Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

From 2023-08-13 to 2023-08-20, AMGN's stock price increased from 258.37 to 259.78. Company news during this period are listed below:

[Headline]: Jefferies Maintains AMGEN (AMGN) Buy Recommendation
[Summary]: 

[Headline]: Mizuho Maintains AMGEN (AMGN) Neutral Recommendation
[Summary]: 

[Headline]: I Got 99 Problems But A High Yield Ain't One (151 Trade Ideas)
[Summary]: Discover how our Advanced cash covered put selling strategy can help you generate high yields while minimizing market risk. Click for our exclusive picks.

[Headline]: Is Now The Time To Put Amgen (NASDAQ:AMGN) On Your Watchlist?
[Summary]: For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

[Headline]: Could Amgen Stock Help You Become a Millionaire?
[Summary]: Healthcare company Amgen (NASDAQ: AMGN) has been a reliable investment to own over what has been a turbulent year for the broader market.  A particularly promising drug involved in the deal is Tepezza, a treatment for thyroid eye disease which could bring in up to $4 billion in peak annual sales.

From 2023-08-20 to 2023-08-27, AMGN's stock price decreased from 259.78 to 254.38. Company news during this period are listed below:

[Headline]: Tracking David Abrams' Abrams Capital Management Portfolio - Q2 2023 Update
[Summary]: Abrams' 13F portfolio value increased from $3.16B to $3.48B this quarter. Click here for a detailed analysis.

[Headline]: Amgen Inc. stock falls Thursday, still outperforms market
[Summary]: Shares of Amgen Inc. dropped 0.29% to $256.62 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...

[Headline]: Amgen Inc. stock falls Friday, underperforms market
[Summary]: Shares of Amgen Inc. slid 0.09% to $256.38 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...

[Headline]: AMGEN PRESENTS LATE-BREAKING PHASE 2 OLPASIRAN DATA AT ESC 2023
[Summary]: Amgen (NASDAQ:AMGN) today announced data from the final analysis of the Phase 2 OCEAN(a)-DOSE study of olpasiran, a small interfering RNA (siRNA) during the Late-Breaking Science Session at the European Society of Cardiology (ESC) Annual Meeting being held in Amsterdam. In the off-treatment extension period, olpasiran showed a lasting effect on Lp(a) reduction nearly a year after the last dose.

[Headline]: UPDATE 2-US FTC suspends challenge to block Amgen's $27.8 bln deal for Horizon Therapeutics
[Summary]: The U.S. Federal Trade Commission (FTC) has suspended its challenge of Amgen's $27.8 billion purchase of Horizon Therapeutics, allowing the FTC to consider whether the agency should settle the case, a filing late on Friday showed.  Amgen said the company was aware of the move and is prepared to demonstrate that there is no legal or factual reason to prohibit the acquisition to the courts.  The agency had said it opposed the deal because of concern that Amgen would leverage its big selling drugs to pressure insurance companies and pharmacy benefit managers to give favorable terms for Horizon's two key products - the fast-growing thyroid eye disease treatment Tepezza and gout drug Krystexxa.

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-08-27, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-08-27 to 2023-09-03) is up by 0-1%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen Inc remains undervalued for value and income investors, indicating potential for future growth and income.
2. The biotech industry has shown resilience during the COVID-19 pandemic, with increasing innovation and investments, which could benefit Amgen as a major player in the market.
3. Amgen has presented positive late-breaking Phase 2 olpasiran data at a prestigious medical conference, showcasing the potential of their products and technologies.

[Potential Concerns]:
1. The earnings growth of Amgen is tracking behind its five-year shareholder returns, indicating potential challenges in generating consistent profitability.
2. The FTC's challenge to block Amgen's acquisition of Horizon Therapeutics could create uncertainty and potential legal hurdles for the company's expansion plans.

[Prediction & Analysis]:
Based on the positive developments and potential concerns mentioned above, as well as the recent stock price movement, it is predicted that Amgen Inc's stock price for the upcoming week (2023-08-27 to 2023-09-03) will increase by 0-1%. Despite the slight decrease in stock price during the past week, the positive factors such as Amgen's undervaluation, the resilience of the biotech industry, and the positive data presentation at a medical conference provide a favorable outlook for the company's stock. However, the potential concerns, specifically the FTC challenge, could create some volatility and uncertainty in the short term. Overall, the positive developments outweigh the potential concerns, leading to a modest increase in Amgen's stock price for the upcoming week."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 145199.14 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-08-13 to 2023-08-20, AMGN's stock price increased from 258.37 to 259.78. Company news during this period are listed below:

[Headline]: Dividend Champion, Contender, And Challenger Highlights: Week Of August 13
[Summary]: A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read more to see the full August 13 weekly update.

[Headline]: Jefferies Maintains AMGEN (AMGN) Buy Recommendation
[Summary]: 

[Headline]: Mizuho Maintains AMGEN (AMGN) Neutral Recommendation
[Summary]: 

[Headline]: I Got 99 Problems But A High Yield Ain't One (151 Trade Ideas)
[Summary]: Discover how our Advanced cash covered put selling strategy can help you generate high yields while minimizing market risk. Click for our exclusive picks.

[Headline]: Amgen Stock Scores Relative Strength Rating Upgrade; Hits Key Benchmark
[Summary]: Amgen shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 68 to 80.

From 2023-08-20 to 2023-08-27, AMGN's stock price decreased from 259.78 to 254.38. Company news during this period are listed below:

[Headline]: Medicare drug price negotiations unlikely to be derailed by lawsuits: UBS
[Summary]: UBS believes there is little chance the lawsuits brought on by pharma companies will delay Medicare pricing negotiations.

[Headline]: Health care stocks: What the market technicals show
[Summary]: Why are UnitedHealth (UNH), Merck & Company (MRK), Johnson & Johnson (JNJ), and Amgen (AMGN), this strategist's top health care stock picks? Freedom Capital Markets Chief Global Strategist Jay Woods joins Yahoo Finance Live to discuss and break down the market technicals of health care stocks.  Woods says he focuses on those four health care stocks, ""because they're in Dow Jones Industrial Average. If you're looking for reasons why the Dow can rally, I give you health care.""  The Health Care Select Sector (XLV) ""continues to make higher lows, as it goes along,"" Woods notes. ""If you're a little skittish on the overall market, health care is a safety sector,"" Woods says.

[Headline]: Amgen : Joins Forces with American Heart Association on Lower Your LDL Cholesterol Now™
[Summary]: A 2023 survey from the American Heart Association with The Harris Poll shows more than half of Americans who have had a heart attack or stroke don't prioritize lowering LDL or bad...

[Headline]: UPDATE 2-SoftBank-backed Neumora Therapeutics files paperwork for U.S. IPO
[Summary]: The filing comes at a time of renewed investor interest in IPOs following a flurry of deals in the United States and European markets, which have over the last year seen many high-profile startups shelve their listing plans due to market volatility.  Neumora's lead drug candidate navacaprant is a potential oral treatment of major depressive disorder.  Neumora did not disclose the size, timetable or other details of the offering in its filing with the U.S. securities regulator.

[Headline]: AMGEN PRESENTS LATE-BREAKING PHASE 2 OLPASIRAN DATA AT ESC 2023
[Summary]: Amgen (NASDAQ:AMGN) today announced data from the final analysis of the Phase 2 OCEAN(a)-DOSE study of olpasiran, a small interfering RNA (siRNA) during the Late-Breaking Science Session at the European Society of Cardiology (ESC) Annual Meeting being held in Amsterdam. In the off-treatment extension period, olpasiran showed a lasting effect on Lp(a) reduction nearly a year after the last dose.

From 2023-08-27 to 2023-09-03, AMGN's stock price increased from 254.38 to 254.71. Company news during this period are listed below:

[Headline]: Horizon (HZNP) Up as FTC Pauses Acquisition by Amgen Lawsuit
[Summary]: The Federal Trade Commission suspends its ongoing lawsuit to block Horizon's (HZNP) acquisition by Amgen until Sep 18, 2023. The company's stock rises 5.8% in response.

[Headline]: FTC suspends challenge to Amgen-Horizon Therapeutics deal
[Summary]: The Federal Trade Commission is suspending its challenge to Amgen's (AMGN) $27.8 billion bid to acquire Horizon Therapeutics (HZNP). The FTC is concerned Amgen will be able to bundle its products to a couple of Horizon's, giving it an advantage over rivals. It's a notion Amgen rejects. The FTC is pausing its challenge in hopes of reaching a settlement that would allow the deal to close. Yahoo Finance Health Care Reporter Anjalee Khemlani breaks the story down.

[Headline]: Amgen Inc. stock rises Tuesday, still underperforms market
[Summary]: Shares of Amgen Inc. rose 1.20% to $259.64 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index...

[Headline]: Amgen gets US FTC's go-ahead for $27.8 billion Horizon deal
[Summary]: The U.S. Federal Trade Commission (FTC) has allowed Amgen to continue its $27.8 billion acquisition of Horizon Therapeutics, while preventing the drugmaker from using anticompetitive tactics to extend the market dominance of two Horizon drugs.  The agreement, announced on Friday, ends months of uncertainty over the deal since the FTC in May filed a lawsuit over concerns that Amgen would leverage its drugs to secure favorable insurance coverage terms for Horizon's thyroid eye disease treatment Tepezza and gout drug Krystexxa.  Under the FTC settlement, Amgen is prohibited from bundling any of its products with Tepezza or Krystexxa, and from using any product rebate or contract term to exclude or disadvantage products that would compete with those drugs.

[Headline]: Amgen’s $27.8 Billion Horizon Takeover Allowed in FTC Accord
[Summary]: (Bloomberg) -- Amgen Inc. can move forward with its $27.8 billion takeover of Horizon Therapeutics Plc after the US Federal Trade Commission said Friday that it accepted a binding settlement that the combined company won’t bundle together two of Horizon’s blockbuster drugs.Most Read from BloombergHuawei Teardown Shows Chip Breakthrough in Blow to US SanctionsMercedes Bets on Range Boost in Swipe at Tesla’s EV LeadWhy China Is Avoiding Using ‘Bazooka’ to Spur EconomyDiamond Prices Are in Free Fal

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-09-03, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-09-03 to 2023-09-10) is up by 1-2%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen's stock price showed an overall positive trend during the past few weeks, with a slight increase in the beginning and a small gain towards the end of the period.
2. Amgen received an upgrade on its IBD Relative Strength Rating from 68 to 80, indicating rising price performance and potential market strength.

[Potential Concerns]:
1. Medicare drug price negotiations may impact Amgen's pricing and profit margins, as discussed by UBS. Legal actions brought by pharma companies could potentially disrupt these negotiations.
2. The ongoing lawsuit and FTC challenge regarding Amgen's acquisition of Horizon Therapeutics bring uncertainty to the deal's closure and potential implications for Amgen's market position.

[Prediction & Analysis]:
Based on the recent positive developments, including the overall upward trend in stock price and the upgrade in IBD Relative Strength Rating, there is a likelihood that Amgen's stock price will continue to climb in the upcoming week. This prediction is also supported by the positive news surrounding the FTC accepting a settlement and allowing Amgen to proceed with its acquisition of Horizon Therapeutics, albeit with certain restrictions. 

However, it's important to consider the potential concerns mentioned, particularly the impact of Medicare drug price negotiations on Amgen's pricing and profitability. Investors should closely monitor any updates related to the lawsuits and challenges to the acquisition deal, as these factors may introduce volatility and uncertainty.

Overall, considering the positive developments and the potential concerns, I predict that Amgen's stock price will increase by 1-2% in the upcoming week."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 145199.14 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-08-13 to 2023-08-20, AMGN's stock price increased from 258.37 to 259.78. Company news during this period are listed below:

[Headline]: Dividend Champion, Contender, And Challenger Highlights: Week Of August 13
[Summary]: A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read more to see the full August 13 weekly update.

[Headline]: Jefferies Maintains AMGEN (AMGN) Buy Recommendation
[Summary]: 

[Headline]: 15 Worst Performing Blue Chip Stocks in 2023
[Summary]: In this piece, we will take a look at the 15 worst performing blue chip stocks in 2023. If you want to skip a background of what’s been going on in this lucrative sector this year, then head on over to 5 Worst Performing Blue Chip Stocks in 2023. In traditional poker, a blue chip […]

[Headline]: I Got 99 Problems But A High Yield Ain't One (151 Trade Ideas)
[Summary]: Discover how our Advanced cash covered put selling strategy can help you generate high yields while minimizing market risk. Click for our exclusive picks.

[Headline]: Is Now The Time To Put Amgen (NASDAQ:AMGN) On Your Watchlist?
[Summary]: For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

From 2023-08-20 to 2023-08-27, AMGN's stock price decreased from 259.78 to 254.38. Company news during this period are listed below:

[Headline]: 11 Most Profitable Biotech Stocks Today
[Summary]: In this piece, we will take a look at the 11 most profitable biotechnology stocks to buy today. If you want to skip our introduction to the biotechnology industry and want to take a look at the top five stocks in this list, then head on over to 5 Most Profitable Biotech Stocks Today. Biotechnology […]

[Headline]: AMGEN TO DISCUSS APPLICATION FOR LUMAKRAS® (SOTORASIB) FOR THE TREATMENT OF KRAS G12C-POSITIVE NSCLC AT FDA ADVISORY COMMITTEE MEETING
[Summary]: Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) will review data supporting the supplemental New Drug Application (sNDA) for the full approval of LUMAKRAS® (sotorasib) for adults with previously treated locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC) at a meeting on Oct. 5, 2023.

[Headline]: These Are the ONLY 3 Biotech Stocks to Consider in August 2023
[Summary]: The world may be on the mend from the grip of the global pandemic, but the consistent drumbeat for medical innovation remains as unyielding as ever. Amid this backdrop, Biotech stocks present a beacon of hope for humanity and a compelling avenue for savvy investors. Delving into the best biotech stocks offers a chance to back businesses spearheading these life-altering breakthroughs and potentially reap massive dividends. American pharmaceutical giants, often overshadowed in global conversations

[Headline]: Amgen Presents Phase 2 OLPASIRan Data at ESC 2023
[Summary]: Amgen announced data from the final analysis of the Phase 2 OCEAN-DOSE study of olpasiran, a small interfering RNA during the Late-Breaking Science Session at the European Society of Cardiology ...

[Headline]: US FTC suspends challenge to block Amgen's $27.8 billion deal for Horizon Therapeutics
[Summary]: Amgen said the company was aware of the move and is prepared to demonstrate that there is no legal or factual reason to prohibit the acquisition to the courts.  The agency had said it opposed the deal because of concern that Amgen would leverage its big selling drugs to pressure insurance companies and pharmacy benefit managers to give favorable terms for Horizon's two key products - the fast-growing thyroid eye disease treatment Tepezza and gout drug Krystexxa.  The Thousand Oaks, California-based company announced plans to buy Horizon in December last year, saying that its rare disease drugs would offer it some protection from the drug pricing provisions of the Inflation Reduction Act, which are aimed at drugs most widely used by the government's Medicare health plan.

From 2023-08-27 to 2023-09-03, AMGN's stock price increased from 254.38 to 254.71. Company news during this period are listed below:

[Headline]: Amgen Inc. stock rises Tuesday, still underperforms market
[Summary]: Shares of Amgen Inc. rose 1.20% to $259.64 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index...

[Headline]: AMGEN TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCE AND THE CITI GLOBAL HEALTHCARE CONFERENCE
[Summary]: Amgen (NASDAQ:AMGN) will present at the 2023 Wells Fargo Healthcare Conference at 9:30 a.m. ET on Wednesday, Sept. 6, 2023. Amgen will also present at the Citi Global Healthcare Conference at 1:00 p.m. ET on Thursday, Sept. 7, 2023. Peter H. Griffith, executive vice president and chief financial officer at Amgen, and Murdo Gordon, executive vice president of global commercial operations at Amgen will present at both conferences. The webcasts from these events will be broadcast over the internet

[Headline]: FTC settles with Amgen over $27.8 billion takeover of Horizon Therapeutics
[Summary]: The Federal Trade Commission reached a deal with Amgen to approve its $27.8 billion acquisition of Horizon Therapeutics plc the agency announced Friday.

[Headline]: CDC: Dividend ETF With Unconventional Market Timing
[Summary]: VictoryShares US EQ Income Enhanced Volatility Wtd is a defensive ETF with unconventional market timing and lower risk in drawdowns. Learn more about CDC here.

[Headline]: Amgen gets green light from FTC for $27.8B Horizon Therapeutics deal
[Summary]: The Federal Trade Commission will allow Amgen to continue a $27.8 billion purchase of Horizon Therapeutics. The companies anticipate closing the deal in the fourth quarter.

From 2023-09-03 to 2023-09-10, AMGN's stock price increased from 254.71 to 257.41. Company news during this period are listed below:

[Headline]: Amgen (AMGN) is a Top-Ranked Momentum Stock: Should You Buy?
[Summary]: Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

[Headline]: Biden FTC’s Antitrust Bark Proves Worse Than Its Bite
[Summary]: Federal Trade Commission Chair  Lina Khan  has been open about her willingness to take on hard cases and lose.  “I’m certainly not someone who thinks success is marked by a 100% court record,” Khan has said.  Frequent defeats, including last week’s settlement with  Amgen  are weakening the agency’s hand, though.

[Headline]: Amgen Inc. (AMGN) Wells Fargo Securities Healthcare Conference (Transcript)
[Summary]: Amgen Inc. (NASDAQ:NASDAQ:AMGN) Wells Fargo Securities Healthcare Conference September 6, 2023 9:30 AM ETCompany ParticipantsArvind Sood - VP of IRPeter Griffith - EVP and CFOConference...

[Headline]: Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
[Summary]: In the latest trading session, Amgen (AMGN) closed at $259.43, marking a +1.98% move from the previous day.

[Headline]: Banker glee does not tell the whole story on Lina Khan setbacks
[Summary]: Settlement over Amgen $28bn acquisition shows the antitrust chief still won concessions to protect consumers

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-09-10, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-09-10 to 2023-09-17) is up by 0-1%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen's stock price showed resilience during the period, with an overall increase from 254.38 to 257.41.
2. Amgen received positive news regarding its acquisition of Horizon Therapeutics, as the Federal Trade Commission settled and approved the $27.8 billion deal.
3. Amgen participated in prominent healthcare conferences, including the Wells Fargo Healthcare Conference and the Citi Global Healthcare Conference, showcasing its presence and expertise in the industry.

[Potential Concerns]:
1. AMGN's stock price underperformed the market during this period, despite the overall increase.
2. The settlement with the Federal Trade Commission over the acquisition of Horizon Therapeutics may indicate regulatory scrutiny and potential challenges in the future.
3. The statement from FTC Chair Lina Khan about the agency's willingness to accept defeats in hard cases may pose uncertainty for Amgen and its future endeavors.

[Prediction & Analysis]:
Based on the positive developments and potential concerns, as well as the overall stock price increase and participation in key conferences, it is reasonable to predict that AMGN's stock price will continue its upward trend during the upcoming week. While there are concerns regarding underperformance and potential regulatory challenges, the overall positive news and resilience of the stock price suggest that investors have confidence in Amgen's capabilities and growth prospects. Therefore, a modest increase of 0-1% is likely for AMGN's stock price in the next week."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 145199.14 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-08-27 to 2023-09-03, AMGN's stock price increased from 254.38 to 254.71. Company news during this period are listed below:

[Headline]: Horizon Therapeutics shares climb after FTC pauses challenge of deal with Amgen
[Summary]: Shares of Horizon Therapeutics PLC gained more than 5% premarket on Monday after the Federal Trade Commission last week paused its legal challenge to Amgen...

[Headline]: Medicare's drug pricing list didn't impact company stocks — here's why
[Summary]: Company stocks were unaffected by the Biden Administration's historic announcement Tuesday of Medicare's first list of drugs for negotiating prices.

[Headline]: Amgen gets US FTC's go-ahead for $27.8 billion Horizon deal
[Summary]: The U.S. Federal Trade Commission (FTC) has allowed Amgen to continue its $27.8 billion acquisition of Horizon Therapeutics, while preventing the drugmaker from using anticompetitive tactics to extend the market dominance of two Horizon drugs.  The agreement, announced on Friday, ends months of uncertainty over the deal since the FTC in May filed a lawsuit over concerns that Amgen would leverage its drugs to secure favorable insurance coverage terms for Horizon's thyroid eye disease treatment Tepezza and gout drug Krystexxa.  Under the FTC settlement, Amgen is prohibited from bundling any of its products with Tepezza or Krystexxa, and from using any product rebate or contract term to exclude or disadvantage products that would compete with those drugs.

[Headline]: AMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION
[Summary]: Amgen (NASDAQ:AMGN) and Horizon Therapeutics plc (NASDAQ:HZNP) today announced the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen's acquisition of Horizon.

[Headline]: Dividend Champion, Contender, And Challenger Highlights: Week Of September 3
[Summary]: A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Click here to read the full September 3 weekly update.

From 2023-09-03 to 2023-09-10, AMGN's stock price increased from 254.71 to 257.41. Company news during this period are listed below:

[Headline]: September Dogs Of The Dow: Walgreens Now Tops All By Yield
[Summary]: There were two Dow Index stocks showing dividends exceeding single share price this month. Click here for a detailed analysis.

[Headline]: Analysis-FTC settlement could shelter Amgen from US price cuts, taxes
[Summary]: The U.S. Federal Trade Commission's decision on Friday to allow Amgen's takeover of Horizon Therapeutics was the latest setback to its stated goal of stricter antitrust enforcement, and instead paved the way for Amgen to gain drugs not subject to new price negotiations and possibly lower the company's tax burden.  The move signals the FTC's uncertainty that a court would support its novel theory of future competition being disadvantaged by Amgen's ""bundling"" of drugs in negotiations with insurers.  ""I think there is some skittishness on whether to pursue this and develop new case law,"" said Abiel Garcia, a partner at Kesselman, Brantly & Stockinger and a former deputy attorney general in California's antitrust department.

[Headline]: Truist Securities Reiterates AMGEN (AMGN) Hold Recommendation
[Summary]: 

[Headline]: Is Amgen A Worthy Investment Despite President Biden's Inflation Reduction Act?
[Summary]: Amgen discovers, develops, manufactures, and delivers human therapeutics worldwide. Find out why we initiate our coverage of AMGN stock with a hold rating.

[Headline]: Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
[Summary]: In the latest trading session, Amgen (AMGN) closed at $259.43, marking a +1.98% move from the previous day.

From 2023-09-10 to 2023-09-17, AMGN's stock price increased from 257.41 to 258.69. Company news during this period are listed below:

[Headline]: September Self-Indexing Strategies For A Possible Blue October
[Summary]: Magic Formula is still one of my favorite broad-based indexing strategies. Find out the top 30 dividend paying Magic Formula stocks scored for September 2023.

[Headline]: Neumora Therapeutics to Sell 14.7 Million Shares at $16-$18 Each in IPO
[Summary]: By Colin Kellaher Neumora Therapeutics, a clinical-stage biopharmaceutical company backed by Amgen, on Monday said it plans to sell 14.7 million shares at between $16 and $18 apiece in its...

[Headline]: Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
[Summary]: Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

[Headline]: Amgen Inc. (AMGN) Morgan Stanley 21st Annual Global Healthcare Conference 2023 (Transcript)
[Summary]: Amgen Inc. (NASDAQ:NASDAQ:AMGN) Morgan Stanley 21st Annual Global Healthcare Conference 2023 September 12, 2023 8:50 AM ETCompany ParticipantsRobert Bradway - Chairman and Chief Executive...

[Headline]: Amgen-partnered AI biotech startup brings in $273M
[Summary]: A biotech startup using generative AI to create new, protein-based medicines has closed on a $273 million round as it looks to expand its reach.

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-09-17, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-09-17 to 2023-09-24) is up by 2-3%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen has received the go-ahead from the US Federal Trade Commission (FTC) for its $27.8 billion acquisition of Horizon Therapeutics. This clears the path for the acquisition and eliminates uncertainty over the deal.
2. The FTC settlement allows Amgen to avoid potential price cuts and taxes, which could have a positive impact on the company's financials.
3. Amgen's stock price has been steadily increasing over the past few weeks, indicating positive investor sentiment.

[Potential Concerns]:
1. The FTC settlement may signal uncertainty regarding the FTC's willingness to pursue stricter antitrust enforcement, potentially impacting future deals and market competitiveness.
2. The absence of basic financials for the company makes it challenging to assess its overall financial health and performance.

[Prediction & Analysis]:
Based on the positive developments mentioned above, the stock price of AMGN is predicted to increase by 2-3% in the upcoming week. The resolution of the FTC lawsuit and the clearance of the acquisition provide a boost to investor confidence and eliminate uncertainties surrounding the deal. Furthermore, the FTC settlement potentially protects Amgen from price cuts and taxes, which could have a positive impact on the company's financials. The consistent increase in stock price over the past few weeks also indicates positive investor sentiment towards the company. However, it is worth noting the absence of basic financials, which makes it difficult to fully assess the company's financial health. Nonetheless, considering the positive news developments and overall market sentiment, a slight increase in the stock price is likely in the upcoming week."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 145199.14 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-09-17 to 2023-09-24, AMGN's stock price increased from 258.69 to 265.61. Company news during this period are listed below:

[Headline]: Argus Research Maintains AMGEN (AMGN) Buy Recommendation
[Summary]: 

[Headline]: Amgen Inc. stock outperforms competitors on strong trading day
[Summary]: Shares of Amgen Inc. rallied 2.71% to $271.46 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...

[Headline]: Best Dividend Stocks: Amgen Hits Buy Point, Offers Solid Dividend Growth
[Summary]: Shares of Amgen have broken out of a cup-with-handle base, another reason why income investors should consider the dividend stock.  The biotech company — headquartered in Thousand Oaks, Calif. — has an assortment of drugs used to treat cancer and autoimmune disorders.  Amgen is best known for it its rheumatoid arthritis drug Enbrel, which contributed 17% of sales last year.

[Headline]: Amgen (AMGN)'s True Worth: A Complete Analysis of Its Market Value
[Summary]: Is Amgen (AMGN) fairly valued? Let's delve into its financials and growth prospects to find out.

[Headline]: Patience Is The Name Of This (Market) Game
[Summary]: Market weakness continues due to concerns about the Fed and interest rates. Read why market weakness during earnings quiet periods may present buying opportunities.

Some recent basic financials of AMGN, reported at 2023-09-30, are presented below:

[Basic Financials]:

assetTurnoverTTM: 0.3207
bookValue: 7656
cashRatio: 2.0491329479768785
currentRatio: 2.8593
ebitPerShare: 3.8848
eps: 3.2156
ev: 168202.84
fcfMargin: 0.3639
fcfPerShareTTM: 17.5308
grossMargin: 0.7385
inventoryTurnoverTTM: 1.4407
longtermDebtTotalAsset: 0.6521
longtermDebtTotalCapital: 0.8667
longtermDebtTotalEquity: 7.7116
netDebtToTotalCapital: 0.3776
netDebtToTotalEquity: 3.3604
netMargin: 0.2506
operatingMargin: 0.3028
payoutRatioTTM: 0.589
pb: 18.6097
peTTM: 18.8311
pfcfTTM: 15.1909
pretaxMargin: 0.2821
psTTM: 5.3097
quickRatio: 2.5629
receivablesTurnoverTTM: 4.6784
roaTTM: 0.0904
roeTTM: 1.2908
roicTTM: 0.123
rotcTTM: 0.147
salesPerShare: 12.8309
sgaToSale: 0.2615
totalDebtToEquity: 7.8981
totalDebtToTotalAsset: 0.6679
totalDebtToTotalCapital: 0.8876
totalRatio: 1.0924

Based on all the information before 2023-09-24, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-09-24 to 2023-10-01) is up by 0-1%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Argus Research maintaining a buy recommendation for Amgen Inc indicates strong confidence in the company's performance and potential growth.
2. Amgen Inc's stock outperforming competitors on a strong trading day suggests positive investor sentiment and demand for the company's shares.
3. Breaking out of a cup-with-handle base is a bullish sign for Amgen as it indicates potential upward momentum and the interest of income investors due to its solid dividend growth.
4. The company's diversified portfolio of drugs, particularly its rheumatoid arthritis drug Enbrel, contributes significantly to its sales and offers stability and growth potential.

[Potential Concerns]:
1. Market weakness due to concerns about the Federal Reserve and interest rates may impact Amgen's stock price as investors assess their impact on the overall market.
2. The overall performance of the stock market can influence Amgen's stock price movement, making it susceptible to broader market trends.

[Prediction & Analysis]:
Based on the positive developments for Amgen Inc, including the buy recommendation, strong trading day performance, and the breakout from a cup-with-handle base, there is an indication of positive momentum and investor sentiment. Additionally, the company's diversified drug portfolio and solid dividend growth provide stability and potential for future growth.

However, potential concerns arise from market weakness due to the Federal Reserve and interest rate concerns, which may affect the overall market sentiment and impact Amgen's stock price.

Considering these factors, a relatively conservative prediction for Amgen's stock price movement for the upcoming week (2023-09-24 to 2023-10-01) would be an increase of 0-1%. While the positive developments and solid fundamentals provide a favorable outlook, the potential concerns and broader market influence temper the prediction to a more cautious range."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 145199.14 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-09-10 to 2023-09-17, AMGN's stock price increased from 257.41 to 258.69. Company news during this period are listed below:

[Headline]: AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS CHEMOTHERAPY DATA IN FIRST-LINE KRAS G12C NSCLC AT WCLC
[Summary]: Amgen (NASDAQ:AMGN) today announced exciting data from a study arm of the CodeBreaK 101 clinical trial, a Phase 1b study evaluating LUMAKRAS® (sotorasib) with carboplatin and pemetrexed in adult patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC). These results were featured in an oral presentation at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC) in Singapore on Sunday, September 10.

[Headline]: Amgen Inc. (AMGN) Morgan Stanley 21st Annual Global Healthcare Conference 2023 (Transcript)
[Summary]: Amgen Inc. (NASDAQ:NASDAQ:AMGN) Morgan Stanley 21st Annual Global Healthcare Conference 2023 September 12, 2023 8:50 AM ETCompany ParticipantsRobert Bradway - Chairman and Chief Executive...

[Headline]: The 3 Most Undervalued Biotech Stocks to Buy in September 2023
[Summary]: It’s been a difficult time for biotechnology stocks. After a boom during the Covid-19 pandemic, the entire sector appears to have been abandoned by investors. The Standards and Practices (S&P) 500 Biotechnology Select Industry Index has declined 11% throughout the past 12 months and is down 18% throughout the last five years. Companies large and small have seen their stock prices slump as investor confidence in the industry wanes. Of course, hurdles surrounding prescription drug makers and medic

[Headline]: Amgen-partnered AI biotech startup brings in $273M
[Summary]: A biotech startup using generative AI to create new, protein-based medicines has closed on a $273 million round as it looks to expand its reach.

[Headline]: Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
[Summary]: In the latest trading session, Amgen (AMGN) closed at $262.30, marking a +1.97% move from the previous day.

From 2023-09-17 to 2023-09-24, AMGN's stock price increased from 258.69 to 265.61. Company news during this period are listed below:

[Headline]: FTC chair targets deals that have fallen in agency's 'blind spots'
[Summary]: FTC chair Lina Khan has her sights focused on challenging mergers & acquisitions in the healthcare and tech sectors, specifically those valued under $100 million. Khan argues that these mergers can snowball into larger monopolies when left unchecked. Senior Reporter for Yahoo Finance Anjalee Khemlani joins to breakdown Lina Khan's recent statement at the Oliver Wyman Health Innovation Summit in Chicago.

[Headline]: IBM, Amgen share gains contribute to Dow's nearly 200-point jump
[Summary]: The Dow Jones Industrial Average is climbing Wednesday morning with shares of IBM and Amgen delivering strong returns for the price-weighted average. The Dow...

[Headline]: Nicholas Ward's Dividend Growth Portfolio: September 2023 Fair Value Update
[Summary]: I've been building my cash position in preparation for a market crash and taking advantage of high interest rates. Read more here.

[Headline]: Amgen (AMGN) Stock Moves -0.76%: What You Should Know
[Summary]: In the latest trading session, Amgen (AMGN) closed at $269.41, marking a -0.76% move from the previous day.

[Headline]: Kyowa Kirin: High-Risk High-Return Call Reiterating Our Buy Rating
[Summary]: Kyowa Kirin's recent track record for new drug trial success has been poor, but the partnership with Amgen provides reassurance. Read why KYKOF stock is a Buy.

From 2023-09-24 to 2023-10-01, AMGN's stock price increased from 265.61 to 266.66. Company news during this period are listed below:

[Headline]: Patience Is The Name Of This (Market) Game
[Summary]: Market weakness continues due to concerns about the Fed and interest rates. Read why market weakness during earnings quiet periods may present buying opportunities.

[Headline]: Beat the Market Like Zacks: Elementis, Novo Nordisk, Amgen in Focus
[Summary]: Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

[Headline]: Dow Jones Biotech Giant Amgen, Meta Stock, Eye Buy Points In Stock Market Correction
[Summary]: Dow Jones biotech leader Amgen and Meta stock are among the best stocks to watch in today's stock market action.

[Headline]: Big Pharma R&D Spending: The Secret Ingredient To Outperformance?
[Summary]: High R&D spending by pharma companies does not necessarily lead to sales growth, let alone shareholder returns. See why bold M&A deals may be a different story.

[Headline]: Amgen Stock Was a Winner in the Third Quarter. These Solar Shares Were Not.
[Summary]: Amgen was the best-performing stock in both the Dow Jones Industrial Average and Nasdaq 100 in the third quarter, while Zions Bancorp, up 32%, was the top stock in the S&P 500.

Some recent basic financials of AMGN, reported at 2023-09-30, are presented below:

[Basic Financials]:

assetTurnoverTTM: 0.3207
bookValue: 7656
cashRatio: 2.0491329479768785
currentRatio: 2.8593
ebitPerShare: 3.8848
eps: 3.2156
ev: 168202.84
fcfMargin: 0.3639
fcfPerShareTTM: 17.5308
grossMargin: 0.7385
inventoryTurnoverTTM: 1.4407
longtermDebtTotalAsset: 0.6521
longtermDebtTotalCapital: 0.8667
longtermDebtTotalEquity: 7.7116
netDebtToTotalCapital: 0.3776
netDebtToTotalEquity: 3.3604
netMargin: 0.2506
operatingMargin: 0.3028
payoutRatioTTM: 0.589
pb: 18.6097
peTTM: 18.8311
pfcfTTM: 15.1909
pretaxMargin: 0.2821
psTTM: 5.3097
quickRatio: 2.5629
receivablesTurnoverTTM: 4.6784
roaTTM: 0.0904
roeTTM: 1.2908
roicTTM: 0.123
rotcTTM: 0.147
salesPerShare: 12.8309
sgaToSale: 0.2615
totalDebtToEquity: 7.8981
totalDebtToTotalAsset: 0.6679
totalDebtToTotalCapital: 0.8876
totalRatio: 1.0924

Based on all the information before 2023-10-01, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-10-01 to 2023-10-08) is down by 0-1%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen presented exciting data from a study showing promising results for LUMAKRAS® in the treatment of advanced non-small cell lung cancer. This demonstrates the company's commitment to innovation and potential for future growth.
2. Amgen partnered with an AI biotech startup, highlighting its focus on leveraging technology for drug discovery and development. This partnership could lead to the creation of new medicines and further enhance Amgen's pipeline.

[Potential Concerns]:
1. The biotechnology sector has been facing challenges, with investor confidence waning and stock prices slumping. This overall sector weakness could impact Amgen's stock price.
2. The FTC chair targets deals in the healthcare sector, specifically those valued under $100 million. Any regulatory challenges or increased scrutiny could potentially impact Amgen's business operations.

[Prediction & Analysis]:
Based on the positive developments and potential concerns, as well as the overall market sentiment, my prediction for Amgen's stock price movement for the upcoming week (2023-10-01 to 2023-10-08) is a slight decrease of 0-1%.

Amgen's presentation of promising data for LUMAKRAS® and its partnership with an AI biotech startup showcase the company's innovative capabilities and potential for future growth. These positive developments could have a positive impact on the stock price. However, the challenges faced by the biotechnology sector and the potential regulatory scrutiny from the FTC chair pose concerns that could limit the stock price's upward momentum.

Considering the overall market sentiment and the potential impacts of the positive developments and concerns, it is likely that the stock price may experience a slight decrease, within the range of 0-1%, in the upcoming week. Investors may exercise caution due to the sector weakness and regulatory uncertainties."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 145199.14 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-09-24 to 2023-10-01, AMGN's stock price increased from 265.61 to 266.66. Company news during this period are listed below:

[Headline]: Beat the Market Like Zacks: Elementis, Novo Nordisk, Amgen in Focus
[Summary]: Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

[Headline]: Earn Double-Digit Income With Options (October 2023)
[Summary]: Earning a decent income from investments higher than the inflation rate is challenging. Check out how we formulate a sustainable and repeatable options income strategy.

[Headline]: The Anti-obesity Drug Market Is About to Get More Crowded
[Summary]: Obesity is an epidemic that affects more than 40% of all American adults, and it's creating a feeding frenzy for investors. With the rise of...

[Headline]: Amgen Stock Was a Winner in the Third Quarter. These Solar Shares Weren’t.
[Summary]: Amgen was the best-performing stock in the Dow Jones Industrial Average in the third quarter, while Zions Bancorp, up 30%, was the top stock in the S&P 500.

[Headline]: Amgen Inc. stock falls Friday, underperforms market
[Summary]: Shares of Amgen Inc. dropped 0.76% to $268.76 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...

From 2023-10-01 to 2023-10-08, AMGN's stock price decreased from 266.66 to 265.38. Company news during this period are listed below:

[Headline]: UPDATE 3-Amgen's late-stage data for lung cancer drug 'not adequate' - FDA staff
[Summary]: The U.S. Food and Drug Administration staff reviewers said on Tuesday Amgen's late-stage study might not be sufficient to confirm the effectiveness for its lung cancer drug, as the firm pursues a traditional nod for the treatment.  Lumakras, which bought in sales of $285 million last year, targets a mutated form of a gene known as KRAS that occurs in about 13% of non-small cell lung cancers - the most common form of the disease.  Amgen's drug was granted accelerated approval by the U.S. FDA in 2021 for advanced lung cancer patients with KRAS mutations whose disease has worsened after treatment with chemotherapy or other medicines.

[Headline]: Gilead Sciences: A Healthy Buy With Solid Dividend
[Summary]: Gilead Sciences has outperformed the S&P 500 with a 19% total return since my last Buy rating in August last year. Learn why GILD stock is a buy.

[Headline]: Large-scale proteomics in population-based studies from UK and Iceland
[Summary]: In a paper released today, deCODE Genetics' scientists shared their findings from a plasma proteomics study performed using affinity-based methods. They analyzed the proteins in the context of diseases and diversity in the sequence of the genome and compared measurements made using two platforms of thousands of proteins in samples from large groups from the UK Biobank and Iceland.

[Headline]: The Zacks Analyst Blog Highlights Amgen, ServiceNow, RTX, Automatic Data Processing and Canadian Pacific Kansas City
[Summary]: Amgen, ServiceNow, RTX, Automatic Data Processing and Canadian Pacific Kansas City are included in this Analyst Blog.

[Headline]: Confirmatory Trial Trouble In KRAS
[Summary]: I wrote last year about KRAS-targeting drugs as cancer therapies, and that pretty much means G12C-KRAS targeting ones.

Some recent basic financials of AMGN, reported at 2023-09-30, are presented below:

[Basic Financials]:

assetTurnoverTTM: 0.3207
bookValue: 7656
cashRatio: 2.0491329479768785
currentRatio: 2.8593
ebitPerShare: 3.8848
eps: 3.2156
ev: 168202.84
fcfMargin: 0.3639
fcfPerShareTTM: 17.5308
grossMargin: 0.7385
inventoryTurnoverTTM: 1.4407
longtermDebtTotalAsset: 0.6521
longtermDebtTotalCapital: 0.8667
longtermDebtTotalEquity: 7.7116
netDebtToTotalCapital: 0.3776
netDebtToTotalEquity: 3.3604
netMargin: 0.2506
operatingMargin: 0.3028
payoutRatioTTM: 0.589
pb: 18.6097
peTTM: 18.8311
pfcfTTM: 15.1909
pretaxMargin: 0.2821
psTTM: 5.3097
quickRatio: 2.5629
receivablesTurnoverTTM: 4.6784
roaTTM: 0.0904
roeTTM: 1.2908
roicTTM: 0.123
rotcTTM: 0.147
salesPerShare: 12.8309
sgaToSale: 0.2615
totalDebtToEquity: 7.8981
totalDebtToTotalAsset: 0.6679
totalDebtToTotalCapital: 0.8876
totalRatio: 1.0924

Based on all the information before 2023-10-08, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-10-08 to 2023-10-15) is up by more than 5%+. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen Inc was the best performing stock in the Dow Jones Industrial Average in the third quarter, indicating strong market performance and investor confidence.
2. Amgen's drug Lumakras was granted accelerated approval by the FDA for advanced lung cancer patients with KRAS mutations, which demonstrates the company's ability to develop effective treatments in the biotechnology sector.

[Potential Concerns]:
1. FDA staff reviewers have raised concerns about the adequacy of Amgen's late-stage study for its lung cancer drug. This uncertainty surrounding the effectiveness of the drug could impact investor sentiment.
2. The competitive landscape in the biotechnology sector is intensifying, with more companies entering the anti-obesity drug market. This increased competition may pose challenges for Amgen to maintain market share.

[Prediction & Analysis]:
Based on the positive developments mentioned above, Amgen Inc has shown strong market performance and the ability to develop innovative treatments. The approval of Lumakras for advanced lung cancer patients with KRAS mutations highlights the company's potential for growth in the biotechnology sector. However, the concerns raised by FDA staff regarding the late-stage study for its lung cancer drug create some uncertainty.

Considering the overall positive outlook and the potential for continued innovation and development, it is likely that Amgen's stock price will increase by more than 5% in the upcoming week. The company's strong market performance, coupled with the approval and success of Lumakras, could attract further investor interest and positively impact the stock price. However, investors should closely monitor any updates or developments related to the concerns raised by the FDA to assess their potential impact on the stock price."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 145199.14 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-10-01 to 2023-10-08, AMGN's stock price decreased from 266.66 to 265.38. Company news during this period are listed below:

[Headline]: Should You Still Buy the Dow Jones' Best-Performing September Stocks?
[Summary]: A handful of blue-chip tickers defied the bigger bearish tide last month, but that doesn't necessarily make these stocks a buy.

[Headline]: UPDATE 2-US FDA panel says Amgen lung cancer drug data cannot be relied on
[Summary]: Advisers to the U.S. Food and Drug Administration on Thursday found that data from a late-stage trial of Amgen's Lumakras could not be relied on, raising questions about the agency's upcoming decision on whether to grant traditional approval of the drug for a type of advanced lung cancer.  The drug was approved by the FDA in 2021 under an accelerated pathway, with confirmatory data a condition for gaining traditional approval.  The main goal of the confirmatory study was progression-free survival (PFS), or how long before the disease begins to worsen, but the FDA questioned some methods used in conducting the trial.

[Headline]: Biotech-Pharma Trade: Buying Opportunities On The Horizon
[Summary]: Concerns over interest rates, pricing erosion, and Medicare's drug price negotiation plan weigh on biotech and pharma sectors. Learn what investors need to know.

[Headline]: Amgen (AMGN) Increases Yet Falls Behind Market: What Investors Need to Know
[Summary]: Amgen (AMGN) closed at $267.47 in the latest trading session, marking a +0.9% move from the prior day.

[Headline]: SCHD: A Magnificent Buy At This Time
[Summary]: The Schwab U.S. Dividend Equity ETF holds well-diversified, high-quality stocks with economies of scale. Explore more details here.

From 2023-10-08 to 2023-10-15, AMGN's stock price increased from 265.38 to 281.88. Company news during this period are listed below:

[Headline]: Amgen upgraded, Texas Instruments downgraded: Wall Street's top analyst calls
[Summary]: Today's top research calls for upgrade, downgrade and initiate on stocks, as compiled by The Fly.

[Headline]: Leerink Partners Upgrades AMGEN (AMGN)
[Summary]: 

[Headline]: Better Passive Income Snowball: SCHD Or DIVO?
[Summary]: We compare two potential core ETFs for building a passive income snowball. Click here to learn which one is a better fit for the investing strategy.

[Headline]: Amgen's (AMGN) Stock Rallies Almost 5% on Broker Upgrade
[Summary]: A Leerink Partner analyst expects accelerating pipeline news flow for Amgen (AMGN).

[Headline]: Is This Dividend Stock a Screaming Buy After Its Latest Acquisition?
[Summary]: Large companies often turn to acquisitions to jump-start revenue and earnings growth or to speed up research and development, among other reasons.  With that said, let's look at the case of biotech giant Amgen (NASDAQ: AMGN), which just closed a blockbuster acquisition of Horizon Therapeutics.  What does Horizon Therapeutics bring?

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-10-15, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-10-15 to 2023-10-22) is down by 1-2%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen's stock price increased from 265.38 to 281.88 during the past week, indicating positive investor sentiment.
2. The stock received an upgrade from Leerink Partners, with the analyst expecting accelerating pipeline news flow for Amgen.

[Potential Concerns]:
1. Advisers to the U.S. FDA found that data from a late-stage trial of Amgen's Lumakras could not be relied on, raising questions about the agency's upcoming decision on traditional approval of the drug.
2. Concerns over interest rates, pricing erosion, and Medicare's drug price negotiation plan continue to weigh on the biotech and pharma sectors.

[Prediction & Analysis]:
Based on the positive developments and potential concerns, it is predicted that Amgen's stock price may decrease by 1-2% in the upcoming week (2023-10-15 to 2023-10-22). While the stock received an upgrade and showed an increase in price during the previous week, the concerns surrounding the reliability of Lumakras trial data and broader sector concerns may dampen investor confidence. Additionally, the lack of basic financials reported may also impact investor sentiment. Therefore, a slight decrease in stock price is expected for the upcoming week."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 145199.14 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-10-15 to 2023-10-22, AMGN's stock price decreased from 281.88 to 276.63. Company news during this period are listed below:

[Headline]: AMGEN TO PRESENT NEW RESEARCH FROM ONCOLOGY PORTFOLIO AND PIPELINE AT ESMO 2023
[Summary]: Amgen (NASDAQ:AMGN) today announced the presentation of new data across its broad oncology portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress 2023, taking place from October 20-24 in Madrid. Results from Amgen-sponsored and collaborative studies, including two late-breaking oral presentations, will feature data in a range of tough-to-treat cancers.

[Headline]: Amgen Inc. stock rises Monday, still underperforms market
[Summary]: Shares of Amgen Inc. inched 0.98% higher to $286.88 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P...

[Headline]: Investors Shun Dividend-Paying Stocks
[Summary]: One aspect of the equity market advance this year is investors' heightened focus on a handful of stocks some are referring to as Magnificent Seven. Read more here.

[Headline]: Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
[Summary]: Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

[Headline]: Oppenheimer Maintains AMGEN (AMGN) Outperform Recommendation
[Summary]: 

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-10-22, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-10-22 to 2023-10-29) is down by more than 5%+. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen's announcement to present new research from its oncology portfolio and pipeline at the ESMO Congress indicates the company's commitment to advancing cancer treatments, which may generate positive attention from investors.
2. Despite the overall positive trading session for the stock market, Amgen's stock price managed to rise by 0.98% on Monday, demonstrating resilience and potential investor confidence in the company.

[Potential Concerns]:
1. The report of investors shunning dividend-paying stocks may have an impact on Amgen, as it is known for its dividend payments. If this trend continues, it could potentially deter investors from considering Amgen as an investment option.
2. The lack of detailed financial information for Amgen raises concerns about the company's financial performance and stability, which could impact investor sentiment.

[Prediction & Analysis]:
Based on the positive developments and potential concerns, as well as the recent stock price decrease, it is likely that Amgen's stock price will continue its downward trajectory in the upcoming week. The lack of detailed financial information, combined with the potential impact of investors shunning dividend-paying stocks, may cause investor uncertainty and lead to a decline in the stock price. Additionally, the absence of any significant positive news or catalysts may limit potential upside potential for the company's stock. Therefore, it is predicted that Amgen's stock price will decrease by more than 5%+ in the next week."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 145199.14 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-10-01 to 2023-10-08, AMGN's stock price decreased from 266.66 to 265.38. Company news during this period are listed below:

[Headline]: Drugmakers sign on to negotiate Medicare prices under protest
[Summary]: All the drugmakers that make the 10 prescription medicines  subject to the first-ever price negotiations for the U.S. Medicare health program, including Amgen and Novartis, said they signed on to participate in the talks by the Oct. 1 deadline.  The penalties for not doing so would have been steep: drugmakers would have to pay 65% to 95% taxes on their drug's Medicare sales or withdraw all of their products from the Medicare and Medicaid programs, which together provide health benefits to 158 million Americans.  ""Merck will sign the initial agreement with CMS under protest,"" the U.S. company said in a statement.

[Headline]: The 10 pharma companies participating in Medicare price negotiations
[Summary]: Ten pharmaceutical manufacturers are signing the Inflation Reduction Act's Medicare drug price negotiation program. These companies are Bristol Myers Squibb (BMY), AstraZeneca (AZN), Boehringer Ingelheim, Immunex, Janssen Pharmaceuticals, Pharmacyclics, Merck & Company (MRK), Janssen Biotech, Novartis (NVS), and Novo Nordisk (NVO), according to the Biden administration. Yahoo Finance Health Care Reporter Anjalee Khemlani discusses the news. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.

[Headline]: Amgen (AMGN) Surpasses Market Returns: Some Facts Worth Knowing
[Summary]: Amgen (AMGN) reachead $265.44 at the closing of the latest trading day, reflecting a +1.7% change compared to its last close.

[Headline]: The Zacks Analyst Blog Highlights Amgen, ServiceNow, RTX, Automatic Data Processing and Canadian Pacific Kansas City
[Summary]: Amgen, ServiceNow, RTX, Automatic Data Processing and Canadian Pacific Kansas City are included in this Analyst Blog.

[Headline]: Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
[Summary]: Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

From 2023-10-08 to 2023-10-15, AMGN's stock price increased from 265.38 to 281.88. Company news during this period are listed below:

[Headline]: SCHD: A Magnificent Buy At This Time
[Summary]: The Schwab U.S. Dividend Equity ETF holds well-diversified, high-quality stocks with economies of scale. Explore more details here.

[Headline]: Amgen's Acquisition Of Horizon Means The Stock Is A Buy
[Summary]: Amgen strengthens its inflammation portfolio and expands globally with the $27.8 billion acquisition of Horizon. Find out if AMGN stock is a buy.

[Headline]: Amgen Stock Surges To 10-Month High, Up 5% On An Unexpected Upgrade
[Summary]: Amgen stock snagged an upgrade Wednesday and surged to a 10-month high as one analyst examined the biotech behemoth's post-Horizon future.

[Headline]: Leerink Partners Upgrades AMGEN (AMGN)
[Summary]: 

[Headline]: Sanofi reaps rewards of immunology investment with eczema results
[Summary]: Pharmaceutical giant set to take on Amgen with atopic dermatitis treatment.

From 2023-10-15 to 2023-10-22, AMGN's stock price decreased from 281.88 to 276.63. Company news during this period are listed below:

[Headline]: Why Investors Need to Take Advantage of These 2 Medical Stocks Now
[Summary]: The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

[Headline]: Amgen Inc. stock rises Monday, still underperforms market
[Summary]: Shares of Amgen Inc. inched 0.98% higher to $286.88 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P...

[Headline]: Dividend Income Update September 2023
[Summary]: With the start of the final quarter of 2023, it’s time to take a look back at my previous month of dividend income.

[Headline]: Amgen Inc. stock underperforms Thursday when compared to competitors
[Summary]: Shares of Amgen Inc. shed 1.05% to $280.60 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...

[Headline]: AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS VECTIBIX® (PANITUMUMAB) DATA IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
[Summary]: Amgen (NASDAQ:AMGN) today announced data from the global Phase 3 CodeBreaK 300 trial evaluating two doses of LUMAKRAS® (sotorasib) (960 mg or 240 mg) in combination with Vectibix® (panitumumab). Both doses demonstrated a statistically significant superiority in progression-free survival (PFS) over the investigator's choice of therapy in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC). The results are being presented today at the Presidential Symposium 2 sessio

From 2023-10-22 to 2023-10-29, AMGN's stock price decreased from 276.63 to 259.53. Company news during this period are listed below:

[Headline]: Amgen Inc. stock outperforms market on strong trading day
[Summary]: Shares of Amgen Inc. advanced 1.12% to $276.12 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...

[Headline]: USA Compression and Disney have been highlighted as Zacks Bull and Bear of the Day
[Summary]: USA Compression and Disney have been highlighted as Zacks Bull and Bear of the Day.

[Headline]: UPDATE 4-AbbVie takes $2.1 bln charge on cancer drug ahead of US price negotiation
[Summary]: AbbVie, girding for government price negotiations on its big-selling cancer drug Imbruvica, on Friday disclosed a $2.1 billion charge related to an expected drop in revenue once the new price for U.S. Medicare patients goes into effect.  The Illinois-based drugmaker's leukemia pill in August was selected as one of the 10 drugs subject to the first-ever price negotiations by U.S. Medicare insurance plans with a stated government goal of saving $25 billion per year on drug costs by 2031.  While new prices for the first 10 drugs have yet to be negotiated and will not go into effect until 2026, AbbVie said it had used an undisclosed placeholder price that led it to estimate ""a significant decrease in the estimated future cash flows"" from the drug.

[Headline]: Xencor: Data In Early 2024 Could Bring Shareholder Value
[Summary]: Xencor is expected to release data from a phase 2 study in early 2024 targeting patients with mCRPC and gynecological cancers. Read more about XNCR stock here.

[Headline]: Apple Headlines Earnings Calendar With Chip Titan AMD, Amgen Also Set To Report
[Summary]: Apple stock is below its 200-day line with earnings due. Advanced Micro Devices and Amgen also report next week.

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-10-29, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-10-29 to 2023-11-05) is up by 3-4%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen signed on to participate in the first-ever price negotiations for the U.S. Medicare health program. This indicates the company's willingness to engage in discussions and potentially reach agreements that could benefit its drug sales.
2. The acquisition of Horizon by Amgen for $27.8 billion strengthens its inflammation portfolio and expands its global presence. This acquisition could lead to future growth opportunities for the company.

[Potential Concerns]:
1. Amgen's stock price has been fluctuating during the past weeks, indicating possible market volatility and uncertainty surrounding the company's performance.
2. Competitors, such as Sanofi, are making strides in developing treatments for diseases that directly compete with Amgen's products, which could potentially impact the company's market share and sales.

[Prediction & Analysis]:
Based on the positive developments, such as Amgen's participation in Medicare price negotiations and the Horizon acquisition, it suggests that the company is proactive in exploring growth opportunities. These factors may contribute to investor confidence and potentially drive the stock price higher. However, the concerns over market volatility and competition should be taken into account.

Considering these factors, it is predicted that Amgen's stock price could increase by 3-4% in the upcoming week. This prediction is based on the assumption that the positive developments will outweigh the potential concerns and attract investors' interest in the company's growth prospects. However, it's important to monitor market conditions and any relevant news that may impact the stock price movement."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 145199.14 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-10-15 to 2023-10-22, AMGN's stock price decreased from 281.88 to 276.63. Company news during this period are listed below:

[Headline]: AbbVie: Successfully Navigating Humira's Patent Cliff With 4% Yield And 270% DGR Since 2014
[Summary]: Despite declining Humira sales, AbbVie remains resilient, focusing on new therapies, M&A, and R&D for sustained growth. Find out why ABBV stock is a Hold.

[Headline]: AMGEN TO PRESENT NEW RESEARCH FROM ONCOLOGY PORTFOLIO AND PIPELINE AT ESMO 2023
[Summary]: Amgen (NASDAQ:AMGN) today announced the presentation of new data across its broad oncology portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress 2023, taking place from October 20-24 in Madrid. Results from Amgen-sponsored and collaborative studies, including two late-breaking oral presentations, will feature data in a range of tough-to-treat cancers.

[Headline]: PBYI vs. AMGN: Which Stock Is the Better Value Option?
[Summary]: PBYI vs. AMGN: Which Stock Is the Better Value Option?

[Headline]: Amgen (AMGN) Stock Moves -0.3%: What You Should Know
[Summary]: Amgen (AMGN) closed the most recent trading day at $283.58, moving -0.3% from the previous trading session.

[Headline]: AMGEN TO WEBCAST INVESTOR CALL AT ESMO 2023
[Summary]: Amgen (NASDAQ:AMGN) today announced that it will host a webcasted call for the investment community at 8:00 a.m. ET on Tuesday, Oct. 24, 2023 following the presentation of new data from Amgen's innovative oncology portfolio including AMG 193 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 and data from tarlatamab, xaluritamig, and LUMAKRAS® (sotorasib) that will be presented at the European Society for Medical Oncology (ESMO) Congress 2023. David

From 2023-10-22 to 2023-10-29, AMGN's stock price decreased from 276.63 to 259.53. Company news during this period are listed below:

[Headline]: AbbVie (ABBV) to Report Q3 Earnings: What's in the Cards?
[Summary]: AbbVie's (ABBV) Q3 performance will likely reflect its newer immunotherapy drugs trying to compensate for declining Humira sales following the loss of U.S. exclusivity.

[Headline]: Oppenheimer Maintains AMGEN (AMGN) Outperform Recommendation
[Summary]: 

[Headline]: 3 Pharma Stocks That Are Screaming Buys in October
[Summary]: It hasn't been the easiest of years for Johnson & Johnson (NYSE: JNJ), Amgen (NASDAQ: AMGN) and Gilead Sciences (NASDAQ: GILD).  Continued uncertainty regarding talc lawsuits is weighing on Johnson & Johnson.  Amgen's huge pipeline hasn't been fully appreciated by the market, and Gilead's settlement of an antitrust lawsuit resulted in lowering yearly earnings per share guidance.

[Headline]: Xencor: Data In Early 2024 Could Bring Shareholder Value
[Summary]: Xencor is expected to release data from a phase 2 study in early 2024 targeting patients with mCRPC and gynecological cancers. Read more about XNCR stock here.

[Headline]: Microsoft Leads These 5 Dow Jones Stocks Near Buy Points
[Summary]: Microsoft, one of just two Magnificent Seven stocks to move higher last week, leads this watchlist of five Dow Jones stocks. near buy points.

From 2023-10-29 to 2023-11-05, AMGN's stock price increased from 259.53 to 267.75. Company news during this period are listed below:

[Headline]: Drug, Biotech Stocks' Q3 Earnings Due on Oct 31: AMGN, PFE, INCY
[Summary]: Let's take a look at three biotech/drug companies, AMGN, PFE and INCY, slated to release quarterly results on Oct 31.

[Headline]: AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS
[Summary]: Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 20231.

[Headline]: Amgen Inc (AMGN) Q3 2023 Earnings: Revenue Up 4% to $6.9 Billion, GAAP EPS Down 19% to $3.22
[Summary]: Amgen Inc (AMGN) reports Q3 2023 financial results, highlighting growth in product sales and pipeline progress

[Headline]: Amgen Inc. 2023 Q3 - Results - Earnings Call Presentation
[Summary]: The following slide deck was published by Amgen Inc.

[Headline]: Amgen Inc. (NASDAQ:AMGN) Q3 2023 Earnings Call Transcript
[Summary]: Amgen Inc. (NASDAQ:AMGN) Q3 2023 Earnings Call Transcript October 31, 2023 Operator: My name is Julianne, and I’ll be your conference facilitator today for Amgen’s Third Quarter 2023 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the conclusion of the […]

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-11-05, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-11-05 to 2023-11-12) is down by 0-1%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen announced the presentation of new data from its oncology portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress 2023. This indicates continued progress in their research and development efforts.
2. Amgen reported growth in product sales and pipeline progress in its Q3 2023 financial results.

[Potential Concerns]:
1. Despite the positive developments, Amgen's stock price experienced a decrease prior to the analyzed period, which suggests possible concerns in the market.
2. The decline in Amgen's GAAP EPS in Q3 2023 may raise concerns about the company's overall financial performance.

[Prediction and Analysis]:
Based on the positive developments and potential concerns, it is predicted that Amgen's stock price may decrease by 0-1% in the upcoming week. The positive news related to new data presentations and growth in product sales and pipeline progress could support the stock price to some extent. However, the previous decrease in stock price and the decline in GAAP EPS in Q3 2023 may contribute to the potential concerns and limit potential upside. It is essential for investors to closely monitor any further developments and financial results of the company to make informed investment decisions."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 145199.14 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-10-15 to 2023-10-22, AMGN's stock price decreased from 281.88 to 276.63. Company news during this period are listed below:

[Headline]: AbbVie: Successfully Navigating Humira's Patent Cliff With 4% Yield And 270% DGR Since 2014
[Summary]: Despite declining Humira sales, AbbVie remains resilient, focusing on new therapies, M&A, and R&D for sustained growth. Find out why ABBV stock is a Hold.

[Headline]: AMGEN TO PRESENT NEW RESEARCH FROM ONCOLOGY PORTFOLIO AND PIPELINE AT ESMO 2023
[Summary]: Amgen (NASDAQ:AMGN) today announced the presentation of new data across its broad oncology portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress 2023, taking place from October 20-24 in Madrid. Results from Amgen-sponsored and collaborative studies, including two late-breaking oral presentations, will feature data in a range of tough-to-treat cancers.

[Headline]: Amgen Inc. stock rises Monday, still underperforms market
[Summary]: Shares of Amgen Inc. inched 0.98% higher to $286.88 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P...

[Headline]: Amgen Inc. stock underperforms Thursday when compared to competitors
[Summary]: Shares of Amgen Inc. shed 1.05% to $280.60 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...

[Headline]: Bond Prices Are Slumping Again. Consider These Dividend ETFs Instead.
[Summary]: Morningstar has identified four dividend funds that hold quality companies and have a proven record.

From 2023-10-22 to 2023-10-29, AMGN's stock price decreased from 276.63 to 259.53. Company news during this period are listed below:

[Headline]: Amgen Inc. stock outperforms market on strong trading day
[Summary]: Shares of Amgen Inc. advanced 1.12% to $276.12 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...

[Headline]: USA Compression and Disney have been highlighted as Zacks Bull and Bear of the Day
[Summary]: USA Compression and Disney have been highlighted as Zacks Bull and Bear of the Day.

[Headline]: Amgen Inc. stock underperforms Wednesday when compared to competitors
[Summary]: Shares of Amgen Inc. slid 1.43% to $272.16 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...

[Headline]: Amgen Inc. stock outperforms market despite losses on the day
[Summary]: Shares of Amgen Inc. dropped 0.90% to $269.71 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...

[Headline]: Apple Headlines Earnings Calendar With Chip Titan AMD, Amgen Also Set To Report
[Summary]: Apple stock is below its 200-day line with earnings due. Advanced Micro Devices and Amgen also report next week.

From 2023-10-29 to 2023-11-05, AMGN's stock price increased from 259.53 to 267.75. Company news during this period are listed below:

[Headline]: Amgen Lifts FY23 Guidance After 3Q Adjusted Profit Tops Estimates
[Summary]: By Ben Glickman Amgen narrowed its full-year guidance for adjusted profit and raised its revenue guidance after third-quarter adjusted profit topped Wall...

[Headline]: Amgen third-quarter sales rise 5%; profit up before charge
[Summary]: Amgen, which earlier this month acquired Horizon Therapeutics for $27.8 billion, on Tuesday said its third-quarter product sales rose 5% as double-digit volume growth was offset by lower prices.  Amgen said it would discuss sales of Horizon's drugs on a conference call with analysts and investors, but raised its post-acquisition forecast for full-year sales to between $28 billion and $28.4 billion from a previous estimate of $26.6 billion to $27.4 billion.  Wall Street analysts, on average, have forecast 2023 earnings of $18.47 per share on revenue of $28 billion, according to LSEG data.

[Headline]: Never Mind Covid, Investors Want a Pfizer Obesity Pill
[Summary]: It is little wonder, then, that investors were hoping Pfizer could jump to the winning camp with an obesity pill.  “Not one mention [of danuglipron] in the prepared remarks from Pfizer,” noted  Will Sevush,  a healthcare strategist for Jefferies.  Before today’s earnings,  David Risinger,  a Leerink Partners analyst, had written that Pfizer might even release data from its mid-stage study alongside the earnings results as soon as Tuesday.

[Headline]: Q3 2023 Amgen Inc Earnings Call
[Summary]: Q3 2023 Amgen Inc Earnings Call

[Headline]: Company News for Nov 01, 2023
[Summary]: Companies In The Article Are: AMGN, NVDA, RGEN, COCO

From 2023-11-05 to 2023-11-12, AMGN's stock price decreased from 267.75 to 265.22. Company news during this period are listed below:

[Headline]: Epidemiology and Genetics of Clonal Hematopoiesis, a Premalignant Hematopoietic Stem Cell Condition
[Summary]: A comprehensive new study from deCODE genetics, a subsidiary of Amgen, published today in Nature Genetics, provides insights into the epidemiology and somatic and germline genetics of clonal hematopoiesis. Whole genome sequence data from Iceland and the UK Biobank, combined with a unique somatic mutation Barcoding strategy, was used to investigate clonal hematopoiesis at the population scale.

[Headline]: Amgen Inc. stock rises Wednesday, outperforms market
[Summary]: Shares of Amgen Inc. inched 0.79% higher to $273.26 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P...

[Headline]: Top 20 Drug Companies in the US by Revenue
[Summary]: In this article, we will be taking a look at the top 20 drug companies in the US by revenue. To skip our detailed analysis, you can go directly to see the Top 5 Drug Companies in the US by Revenue. Following the Covid-19 pandemic, which drastically altered the way of living, the top pharmaceutical […]

[Headline]: Amgen, Home Depot share losses contribute to Dow's 150-point drop
[Summary]: Shares of Amgen and Home Depot are trading lower Thursday afternoon, sending the Dow Jones Industrial Average into negative territory. The Dow was most...

[Headline]: Amgen Inc. stock rises Friday, still underperforms market
[Summary]: Shares of Amgen Inc. rose 1.23% to $267.31 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index...

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-11-12, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-11-12 to 2023-11-19) is up by 0-1%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen Inc. presented new research from its oncology portfolio and pipeline at the ESMO Congress 2023, showcasing its commitment to developing treatments for tough-to-treat cancers.
2. Amgen Inc. announced narrowed full-year guidance for adjusted profit and raised its revenue guidance after reporting strong third-quarter results, indicating positive performance and growth prospects.

[Potential Concerns]:
1. Amgen Inc.'s stock price underperformed against the market on some days, suggesting potential market skepticism or uncertainty surrounding the company.
2. The company experienced a slight decline in stock price during the analyzed period, indicating possible investor hesitance or lack of positive sentiment.

[Prediction & Analysis]:
Based on the positive developments of Amgen Inc.'s research presentations in the oncology field and the company's strong financial performance indicated by narrowed guidance and increased revenue forecasts, there are indications of potential positive momentum in the stock price. However, the concerns surrounding the underperformance on some trading days and the overall decline in stock price suggest some market hesitancy or lack of conviction.

Considering these factors, it is predicted that Amgen Inc.'s stock price for the upcoming week (2023-11-12 to 2023-11-19) will have a slight increase of around 0-1%. This prediction is based on the expectation that the positive developments and strong financial performance demonstrated by the company will outweigh the concerns and contribute to a moderate upward movement in the stock price. However, it is important to closely monitor market sentiment and any potential additional news or developments that may impact the stock price."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 145199.14 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-11-12 to 2023-11-19, AMGN's stock price increased from 265.22 to 265.39. Company news during this period are listed below:

[Headline]: 6 intriguing stocks investors should consider: Piper Sandler
[Summary]: The market has slightly rebounded, with some investors excited for a possible Santa Claus rally to close out the year. Piper Sandler's technical research team announced six stocks that are currently looking attractive for investor portfolios: Amazon (AMZN), Amgen Inc. (AMGN), Coterra Energy (CTRA), Lululemon (LULU), Assurant (AIZ), and Palo Alto Networks (PANW). Jason Glazer, Piper Sandler & Co. Managing Director and Head of Product Management, joins Yahoo Finance to break down the company's picks, how they arrived there, and give insight into the chosen stocks. ""[Lululemon] stands out because it has both high earnings growth and earnings expectations and if you go into the business they have pretty high margins with about 45% of sales coming from company-owned sales and 45% of sales coming through the e-commerce channel,"" Glazer explains. ""They're tremendous at product innovation, they keep full-price selling, unlike a lot of the discounting you see in the retail industry, and they also have some tremendous growth opportunities in China."" For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.

[Headline]: Amgen Is Still A Hold, But Should Be On Your Watchlist
[Summary]: Amgen is a resilient healthcare company that tends to perform well in challenging business environments. See why I think AMGN stock is still a hold.

[Headline]: Amgen: Buy In Stable Fundamental And Technical Price Growth
[Summary]: Amgen's Q3 2023 financial performance showed increased total revenues and product sales, driven by volume growth and strong international markets. Click here to read my analysis.

[Headline]: Amgen Inc. stock falls Friday, underperforms market
[Summary]: Shares of Amgen Inc. shed 1.34% to $265.39 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index...

[Headline]: Tracking George Soros' 13F Portfolio - Q3 2023 Update
[Summary]: George Soros' 13F portfolio value increased by 10% to $7.05B. Click here to read more about Soros Fund Management's holdings and trades for Q3 2023.

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-11-19, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-11-19 to 2023-11-26) is up by 0-1%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen Inc. has been listed as one of the six intriguing stocks for investors to consider by Piper Sandler, which could attract more attention and potential investment influx.
2. Amgen's Q3 financial performance showcased increased total revenues and product sales, indicating strong growth in volume and international markets.

[Potential Concerns]:
1. Amgen Inc.'s stock price fell by 1.34% recently, underperforming the market trend, indicating a possible lack of short-term positive catalysts.
2. The lack of basic financials reported could raise concerns regarding the company's financial stability and performance.

[Prediction & Analysis]:
Based on the positive developments, such as being recognized as an attractive stock by Piper Sandler and strong financial performance demonstrated in Q3, there is potential for Amgen Inc.'s stock price to increase in the upcoming week. However, the recent underperformance of the stock and the absence of reported basic financials could raise concerns and hinder significant upward movement. Therefore, the prediction for the stock price movement for the upcoming week is a slight increase of 0-1%. Investors should closely monitor any developments and announcements from Amgen Inc. to gauge the potential for further growth."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 145199.14 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-10-29 to 2023-11-05, AMGN's stock price increased from 259.53 to 267.75. Company news during this period are listed below:

[Headline]: Drug, Biotech Stocks' Q3 Earnings Due on Oct 31: AMGN, PFE, INCY
[Summary]: Let's take a look at three biotech/drug companies, AMGN, PFE and INCY, slated to release quarterly results on Oct 31.

[Headline]: Amgen (AMGN) Beats on Q3 Earnings Beat, Lags Sales, Ups View
[Summary]: Amgen (AMGN) beats Q3 estimates for earnings but misses on sales. Following the acquisition of Horizon Therapeutics, it raises earnings and sales guidance for 2023.

[Headline]: Never Mind Covid, Investors Want a Pfizer Obesity Pill
[Summary]: It is little wonder, then, that investors were hoping Pfizer could jump to the winning camp with an obesity pill.  “Not one mention [of danuglipron] in the prepared remarks from Pfizer,” noted  Will Sevush,  a healthcare strategist for Jefferies.  Before today’s earnings,  David Risinger,  a Leerink Partners analyst, had written that Pfizer might even release data from its mid-stage study alongside the earnings results as soon as Tuesday.

[Headline]: Amgen gets FDA approval for its inflammatory diseases treatment Wezlana
[Summary]: Amgen has received approval from the U.S. Food and Drug Administration for Wezlana, its treatment for multiple inflammatory diseases.

[Headline]: AMGEN TO PRESENT DATA AT ACR 2023 ACROSS EXPANDED RHEUMATOLOGY PIPELINE AND PORTFOLIO
[Summary]: Amgen (NASDAQ:AMGN) today announced the presentation of new scientific and clinical research across its expanded rheumatology pipeline and portfolio, following the recent acquisition of Horizon Therapeutics. More than 20 abstracts will be presented during the American College of Rheumatology (ACR) Convergence 2023, taking place Nov. 10-15, in San Diego.

From 2023-11-05 to 2023-11-12, AMGN's stock price decreased from 267.75 to 265.22. Company news during this period are listed below:

[Headline]: November Dogs Of The Dow: 3 Buyable, 4 Watchable
[Summary]: Learn about the Dow Jones Industrial Average and the top-performing stocks in November. Click to see our exclusive list of dividend stocks we consider buyable now.

[Headline]: High Yield Stock Watchlist - November 2023
[Summary]: The majority of the 22 stocks on my high yield watchlist for November 2023 are undervalued based on dividend yield theory. Click here for the complete list.

[Headline]: Amgen Inc. stock falls Tuesday, underperforms market
[Summary]: Shares of Amgen Inc. slipped 0.63% to $271.11 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...

[Headline]: Top 20 Drug Companies in the US by Revenue
[Summary]: In this article, we will be taking a look at the top 20 drug companies in the US by revenue. To skip our detailed analysis, you can go directly to see the Top 5 Drug Companies in the US by Revenue. Following the Covid-19 pandemic, which drastically altered the way of living, the top pharmaceutical […]

[Headline]: 2 Top Biotech Stocks to Buy Right Now
[Summary]: It's been a rough year for the biotech industry, which as a whole has substantially lagged the broader market.  Two worth a closer look today are Amgen (NASDAQ: AMGN) and Moderna (NASDAQ: MRNA) whose prospects really don't look as bad as their year-to-date performances suggest.  At current levels, both Amgen and Moderna are worth investing in now.

From 2023-11-12 to 2023-11-19, AMGN's stock price increased from 265.22 to 265.39. Company news during this period are listed below:

[Headline]: 6 intriguing stocks investors should consider: Piper Sandler
[Summary]: The market has slightly rebounded, with some investors excited for a possible Santa Claus rally to close out the year. Piper Sandler's technical research team announced six stocks that are currently looking attractive for investor portfolios: Amazon (AMZN), Amgen Inc. (AMGN), Coterra Energy (CTRA), Lululemon (LULU), Assurant (AIZ), and Palo Alto Networks (PANW). Jason Glazer, Piper Sandler & Co. Managing Director and Head of Product Management, joins Yahoo Finance to break down the company's picks, how they arrived there, and give insight into the chosen stocks. ""[Lululemon] stands out because it has both high earnings growth and earnings expectations and if you go into the business they have pretty high margins with about 45% of sales coming from company-owned sales and 45% of sales coming through the e-commerce channel,"" Glazer explains. ""They're tremendous at product innovation, they keep full-price selling, unlike a lot of the discounting you see in the retail industry, and they also have some tremendous growth opportunities in China."" For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.

[Headline]: 13 Cheap Blue Chip Stocks To Buy
[Summary]: In this piece, we will take a look at the 13 cheap blue chip stocks to buy. To skip our overview of the blue chip sector and the latest news about the stock market, take a look at the 5 Cheap Blue Chip Stocks To Buy. Within the American stock market, the Dow Jones Industrial […]

[Headline]: Amgen Inc's Dividend Analysis
[Summary]: Amgen Inc(NASDAQ:AMGN) recently announced a dividend of $2.13 per share, payable on 2023-12-08, with the ex-dividend date set for 2023-11-16.  As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates.  Using the data from GuruFocus, let's look into Amgen Inc's dividend performance and assess its sustainability.

[Headline]: Amgen Inc. stock outperforms market on strong trading day
[Summary]: Shares of Amgen Inc. rose 1.11% to $273.03 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...

[Headline]: Amgen Inc. stock falls Thursday, underperforms market
[Summary]: Shares of Amgen Inc. slipped 0.70% to $269.00 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...

From 2023-11-19 to 2023-11-26, AMGN's stock price increased from 265.39 to 265.46. Company news during this period are listed below:

[Headline]: 18 Best-Performing Dow Stocks in 2023
[Summary]: In this article, we will take a look at the 18 best-performing Dow stocks in 2023. To see more such companies, go directly to 5 Best-Performing Dow Stocks in 2023. The economy and stock markets have defied almost every prediction and estimate in 2023. When the year started there was almost a consensus among notable […]

[Headline]: Tracking George Soros' 13F Portfolio - Q3 2023 Update
[Summary]: George Soros' 13F portfolio value increased by 10% to $7.05B. Click here to read more about Soros Fund Management's holdings and trades for Q3 2023.

[Headline]: Billionaire Steven Cohen’s Top High Dividend Stock Picks
[Summary]: In this article, we discuss billionaire Steve Cohen’s top high-dividend stock picks. You can skip our detailed analysis of Point72 Asset Management’s holding and recent developments, and go directly to read Billionaire Steven Cohen’s Top 5 High Dividend Stock Picks. Steve Cohen is a prominent figure in the world of finance and investing, known for […]

[Headline]: Amgen Inc. stock falls Tuesday, underperforms market
[Summary]: Shares of Amgen Inc. dropped 0.95% to $262.82 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...

[Headline]: Merck: Keytruda Patent Expiry Nears With Replacement Yet To Be Found
[Summary]: For now, Merck's prospects have somewhat dimmed, with management engaging on expensive partnerships to boost its pipelines. Learn why we rate MRK stock a hold.

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-11-26, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-11-26 to 2023-12-03) is up by 0-1%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen received FDA approval for its inflammatory diseases treatment, Wezlana, which indicates positive progress in the company's pipeline and potential for revenue growth.
2. The acquisition of Horizon Therapeutics has allowed Amgen to expand its rheumatology pipeline and portfolio, which will be presented at the American College of Rheumatology (ACR) event. This showcases the company's commitment to research and development and highlights potential future opportunities.

[Potential Concerns]:
1. The recent stock price decrease and underperformance compared to the market may raise concerns about Amgen's ability to maintain its growth momentum and investor confidence.
2. The decreasing stock price over the past week, despite some positive news, suggests that investors may have concerns about the company's overall performance and potential challenges in the biotechnology industry.

[Prediction & Analysis]:
Based on the positive developments such as FDA approval for Wezlana and the expansion of the rheumatology pipeline, Amgen shows potential for growth and increased revenue generation. However, the recent stock price decrease and underperformance compared to the market are concerning factors. 

For the upcoming week, a prediction of a slight increase in the stock price by 0-1% seems plausible. The positive developments in the company's pipeline and the upcoming presentation at the ACR conference could generate positive sentiment among investors. However, the concerns regarding the recent stock price performance may limit the extent of the increase. Additionally, overall market conditions and investor sentiment towards the biotechnology sector will also influence Amgen's stock price movement."
